

CURRICULUM VITAE

(updated February 2023)

Name: Andrew Blauvelt, M.D., M.B.A.

Date and Place of Birth: February 12, 1962, Ypsilanti, MI

Work Address:

9495 SW Locust Street

Suite G

Portland, OR 97223

Phone: 503-245-1525

Fax: 503-245-0315

E-mail: ablauvelt@oregonmedicalresearch.com

Education/Training:

- 1980-1984 B.S., Electrical Engineering, Purdue University, West Lafayette, IN
- 1984-1988 M.D., Michigan State University, East Lansing, MI
- 1988-1989 Intern, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI
- 1989-1992 Dermatology Resident, Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL
- 1992-1995 Postdoctoral Fellow, Dermatology Branch (in the laboratory of Stephen I. Katz, M.D., Ph.D.), National Cancer Institute, Bethesda, MD
- 1995-1996 Postdoctoral Fellow, Molecular Virology Section (in the laboratory of Kuan-Teh Jeang, M.D., Ph.D.), Laboratory of Molecular Microbiology, National Institute for Allergy and Infectious Diseases, Bethesda, MD
- 2010-2013 M.B.A. in Healthcare Management, Oregon Health & Science University/Portland State University, Portland, OR

Employment:

- 1996-2003 Investigator (Tenure-Track) and Head, Viral Pathogenesis Section, Dermatology Branch, National Cancer Institute, Bethesda, MD
- 2003-2004 Senior Investigator (Tenured) and Head, Viral Pathogenesis Section, Dermatology Branch, National Cancer Institute, Bethesda, MD
- 1999-2001 Adjunct Assistant Professor, Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD
- 2001-2004 Adjunct Associate Professor, Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD
- 2004-2011 Adjunct Professor, Department of Dermatology, Uniformed Services University, Bethesda, MD
- 2004-2011 Professor, Department of Dermatology, Oregon Health & Science University, Portland, OR
- 2004-2011 Professor, Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR

2004-2011 Chief, Dermatology Service, Veterans Affairs Medical Center, Portland, OR
2011-present Affiliate Professor, Department of Dermatology, Oregon Health & Science University, Portland, OR
2011-present Investigator, Oregon Medical Research Center, Portland, OR
(<http://www.oregonmedicalresearch.com/>)
2011-2014 Private practice, Klein Dermatology & Associates, Portland, OR
2013-2022 President and Owner, Oregon Medical Research Center, Portland, OR
2014-2015 Private practice, Dermatology Associates, Portland, OR
2015-2020 Private practice, Baker Allergy, Asthma & Dermatology, Portland, OR

Uniformed Service:

1992-1993 U.S. Public Health Service (Lieutenant)
1993-1997 U.S. Public Health Service (Lieutenant Commander)
1997-2004 U.S. Public Health Service (Commander)

Certification/Licensure:

1989 Diplomate, National Board of Medical Examiners
1992 Certification in Dermatology, American Board of Dermatology
1993 Certification in Clinical and Laboratory Dermatological Immunology, American Board of Dermatology
1991-2004 Medical License, State of Maryland
2001-present Re-certification in Dermatology, American Board of Dermatology
2004-present Medical License, State of Oregon

Professional Societies and Activities:

American Academy of Dermatology (1990-present)

- Sexually Transmitted Diseases Task Force (1994-1995)
- Invited Speaker, Stephen Rothman Club (1998, 2003)
- Study Group on Medical Dermatology (1999)
- Psoriasis Task Force/Expert Resource Group (2000-2004)
- HIV/STD Task Force/Expert Resource Group (2000-2004)
- Invited participant, Forum for Future Leaders in Dermatology (2002)
- Invited chairperson, Residents & Fellows Symposium, Annual Meeting (2002-2005)
- Invited participant, Psoriasis Therapies Educational Summit (2002)
- Invited member, Research Committee (2007-2009)
- Invited member, Congressional Policy Committee (2009-2010)
- Invited member, Camp Discovery Committee (2011-2013)
- Invited Member, Late Breaker Review Committee (2015-present)
- Invited member, Atopic Dermatitis Education Task Force (2019-present)

Society for Investigative Dermatology (1994-present)

- Investigator/Fellow Dinner Program (1997-2007)
- Education for Students Program (1999-2007)

- Committee on Albert M. Kligman Fellowships (2000-2004)
- Committee on Clinical Scholars Program (2001-2004)
- Invited chairperson, minisymposia at annual meetings (2001, 2003-2004, 2007-2008, 2010)
- Invited speaker, retreat to recruit physician-scientists (2001, 2003)
- Chairperson, Committee on Resident and Fellow Programs (2002-2005)
- Invited abstract reviewer for annual meetings (2003-2005, 2010)
- Invited Co-Chair, Psoriasis Research Symposium, 2017

Washington D.C. Dermatological Society (1996-2004)

American Association for the Advancement of Science (1996-2010)

American Society for Microbiology (1997-2006)

American Association of Immunologists (1997-2010)

Dermatology Foundation (1998-2011)

- Invited member, Medical and Scientific Committee (2004-2007)
- Invited chairperson, Medical and Scientific Committee (2007)
- Invited Vice Chairman for the State of Oregon (2006-2007)
- Leader's Society (2006-2011)

National Psoriasis Foundation (1998-present)

- Professional member (1998-present)
- Invited member, Medical Advisory Board (2001-2004, 2007-2013)
- Invited member, Board of Trustees Research Committee (2004)
- Selected Honorary Medical Chair, Walk to Cure Psoriasis in Portland (2007-2010)
- Invited member, Scientific Advisory Board (2009-2014)
- Member, President's Council (2009-present)
- Invited member, Translational Grant Review Committee (2011)
- Invited member, Emeritus Medical Board (2015-present)
- Invited member, Scientific Advisory Committee (2016-present)
- Invited member, COVID-19 Task Force (2020-present)

American Society for Clinical Investigation (2004-2012)

Oregon Dermatology Society (2004-present)

- Board of Directors (2010-2013)
- President-elect (2010-2011)
- President (2011-2012)
- Immediate Past President (2012-2013)

Oregon Medical Association (2004-present)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (2006-present)

American Dermatological Association (2007-present)

- Member, Meeting Site Committee (2008-2011)

Invited Scientific Program Co-Chair, "The Biologic Basis of Psoriasis," 57th Annual Montagna Symposium on the Biology of Skin (2008)

Pacific Dermatologic Association (2008-2009)

- Invited Scientific Program Chair for the annual meeting (2009)

Clinical Immunology Society, invited session chair at annual meeting (2010)

Association of Professors of Dermatology (2010-2011)

Invited Member, Executive Committee, Dermatology Comparative Effectiveness Research Network (2010-2015)

Invited Councilor, International Psoriasis Council (2011-present)

- Chair, Biosimilars Working Group (2013-2016)
- Member, Patient Care Committee (2017-present)
- Member, Moderate Psoriasis Committee (2017-present)
- Member, Disease Severity Committee (2020-present)
- Invited Member, Board of Directors (2022-present)

Member, Pediatric Dermatology Research Alliance Guidance Document for Industry Committee (2016-2017)

Member, European Academy of Dermatology and Venereology (2017-present)

Invited Councilor, International Eczema Council (2019-present)

Committees and Local Activities:

Volunteer dermatologist, Whitman-Walker Clinic, Washington, D.C. (1997-1999)

Invited member, Search Committee for Dermatology Branch Clinical Researcher (1998)

Invited ad hoc reviewer, NIH extramural (NIAID and NIAMS) grants in immunology, HIV/AIDS, and dermatology (1998-2005)

Member, NCI Institutional Review Board (1999-2001)

Invited lecturer, International Society for Infectious Diseases International HIV/AIDS Training Program (1999-2002)

Member, NIH AIDS Malignancy Working Group (1999)

Interviewer of prospective medical students, Uniformed Services University of the Health Sciences (1999-2003)

Member, Trans-NIH Microbicide Working Group (1999-2004)

Member, NIH Pharmacy and Therapeutics Committee (2000-2004)

Invited abstract judge, NIH Fellows Award for Research Excellence (2001-2003)

Member, NCI HIV and Cancer Virology Faculty (2001-2004)

Member, NCI Immunology Faculty (2001-2004)

Member, NCI Vascular Biology Faculty (2001-2004)

Invited member, Search Committee for Dermatology Branch Staff Clinician (2002)

Invited member, Research Evaluation and Decision Panel for the AIDS and Cancer Specimen Resource (2004)

Member, OHSU Cancer Institute (2004-2009)

Member, Medical Staff Council, Portland VA Medical Center (2004-2011)

Faculty Coordinator, OHSU Department of Dermatology Basic Science Journal Club (2004-2011)

Faculty Coordinator, OHSU Department of Dermatology Resident Research Rotation (2004-2011)

Member, OHSU Department of Dermatology Executive Committee (2004-2011)

Founder and Director, OHSU Center of Excellence for Psoriasis and Psoriatic Arthritis (CEPPA) (2006-2011)

Invited ad hoc member, OHSU thesis defense committee for Ph.D. candidate, Cortny Huddleston (2006)

Invited member, Oregon Health Plan Subcommittee on Targeted Immune Modulators (2007)

Invited participant, Roundtable discussion on psoriasis, psoriatic arthritis, and rheumatoid arthritis sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (2007)

Invited member, OHSU qualifying examination committee for Ph.D. candidate, Kalmia Buels (2007)

Volunteer, Oregon Museum of Science and Industry Body Worlds exhibit (2007)

Member, OHSU Department of Dermatology Storrs Lectureship Committee (2009-2012)

Faculty advisor to OHSU medical students: Brian Truong, Courtney Bell, Janelle Minter (2009-2011)

Volunteer mentor, OHSU Science Class Program for high school students (2010)

Volunteer, OHSU head & neck cancer screening (2010)

Invited ad hoc reviewer, Oregon Clinical and Translational Research Institute pilot grant Program (2010)

Invited member, Aarhus University thesis defense committee for Ph.D. candidate, Claus Johansen (2010)

Director, OHSU Department of Dermatology Kingery Library Committee (2010-2011)

Faculty Advisor, Dermatology Interest Group for OHSU medical students (2010-2011)

Faculty advisor to OHSU dermatology training grant pre-doctoral student: Joshua Walker (2010-2011)

Reviewer for Pharmacy Committee Recommendations and Policy, Regence Blue Cross/Blue Shield, Portland, OR (2010-present)

Volunteer dermatologist, Wallace Medical Concern, Portland, OR (2013-2017)

Faculty thesis advisor to OHSU doctoral student: Sarah Siegel (2016-2020)

Invited Member, Advance AD Clinical Quality Program (2021-present)

Journal Activities:

Editorial Board, *Journal of the American Academy of Dermatology* (1998-2007)

Feature Editor, "Dermatology Grand Rounds at the NIH," *Journal of the American Academy of Dermatology* (2000-2004)

Assistant Editor, *Journal of the American Academy of Dermatology* (2004)

Associate Editor (Science), *Journal of the American Academy of Dermatology* (2004-2007)

International Advisory Board, *Journal of Dermatology* (2000-present)

Associate Editor, *Journal of Investigative Dermatology* (2002-2009)

Editorial Board, *Journal of Dermatological Science* (2003-present)

Section Head, "Psoriasis & Other Inflammatory Diseases" and Dermatology Advisory Board, Faculty of 1000 Medicine (2004-2011)

Editorial Board, *Psoriasis Forum* (2006-2019)

Editorial Board, *Annals of Dermatology* (2009-2011)

Section Editor (Immunology/Infection), *Journal of Investigative Dermatology* (2009-2011)

Board of Consulting Editors, *Journal of Clinical Investigation* (2010-2012)

Editorial Board, *Journal of Clinical and Experimental Dermatology* (2010-2011)
Associate Editor, Translational Research, *British Journal of Dermatology* (2019-2022)
Senior Editor, *Journal of Psoriasis and Psoriatic Arthritis* (2020-present)
Associate Editor, *Journal of Investigative Dermatology* (2022-present)
Reviewer: *New England Journal of Medicine*, *The Lancet*, *Science*, *Journal of Experimental Medicine*, *Proceedings of the National Academy of Sciences*, *Journal of Clinical Investigation*, *Journal of Biological Chemistry*, *Journal of Immunology*, *Journal of Allergy and Clinical Immunology*, *Journal of Leukocyte Biology*, *Immunology Letters*, *Journal of Immunological Methods*, *Journal of Immunotherapy*, *Clinical Immunology*, *International Immunology*, *Expert Review of Clinical Immunology*, *The Lancet Infectious Diseases*, *Journal of Virology*, *Virology*, *AIDS*, *AIDS Research and Human Retroviruses*, *Journal of the Acquired Immune Deficiency Syndrome*, *Antiviral Therapy*, *Journal of Infectious Diseases*, *Clinical Infectious Diseases*, *Clinical and Microbiological Reviews*, *Journal of the National Cancer Institute*, *Cancer Research*, *Blood*, *Current Molecular Medicine*, *Expert Reviews in Molecular Medicine*, *Journal of Cellular Physiology*, *F100 Biology Reports*, *Clinical Science*, *Hepatology*, *American Journal of Pathology*, *Arthritis and Rheumatism*, *Annals of Epidemiology*, *Journal of Investigative Dermatology*, *Archives of Dermatology*, *Journal of the American Academy of Dermatology*, *British Journal of Dermatology*, *Journal of Dermatological Science*, *Journal of Dermatological Treatment*, *Journal of Dermatology*, *Experimental Dermatology*, *Journal of the European Academy of Dermatology and Venereology*, *Annals of Dermatology*, *Dermatologic Surgery*, *American Journal of Contact Dermatitis*, *Psoriasis Forum*, *Medical Hypotheses*, *The Medical Letter*, *British Journal of Ophthalmology*

Clinical Study Activities:

1. 1996-2003, Principal Investigator for NIH intramural study #76-C-0293, "Induction of suction blisters in patients with urticaria, blistering diseases, inflammatory dermatoses and neoplastic disorders, and in normal volunteers"
2. 1996-1999, Principal Investigator for NIH intramural study #93-C-0050, "Induction of suction blisters in HIV-infected patients"
3. 1998-2004, Principal Investigator for NIH intramural study #96-C-0097, "The acquisition of blood and skin samples from patient volunteers to support research activities on dermatologic diseases"
4. 1999-2000, Principal Investigator for NIH intramural study #99-C-0027, "Randomized double-blind placebo-controlled trial using recombinant human interleukin-10 for moderate-to-severe psoriasis"
5. 2000-2002, Principal Investigator for NIH intramural study #00-C-0211, "A pilot open-label single-dose study using intravenous micellar paclitaxel for patients with severe psoriasis"
6. 2001, Principal Investigator for NIH intramural study #02-C-0246, "Validation of a survey instrument for future psoriasis studies"

7. 2004, Principal Investigator for NIH intramural study #04-C-0036, "Induction of suction blisters in healthy volunteers"
8. 2004-2005, Co-investigator for OHSU study #578, "Efalizumab for moderate to severe atopic dermatitis - a phase I pilot study in adults"
9. 2005-2009, Principal Investigator for OHSU study #1630, "Expression of p19, p40, and p35 in skin"
10. 2006-2011, Principal Investigator for OHSU study #2364, "A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis (PHOENIX 2)"
11. 2006-2011, Principal Investigator for OHSU study #2568, "Role of IL-23 and other cytokines in psoriasis and atopic dermatitis pathogenesis"
12. 2006-2010, Principal Investigator for OHSU study #2938, "Induction of suction blisters in healthy volunteers"
13. 2006-2007, Co-investigator for OHSU study #2570, "A phase 3, randomized, double-blind study to evaluate the efficacy and safety of BID application of tacrolimus cream-B 0.1% versus cream-B vehicle in the treatment of psoriasis"
14. 2008-2010, Principal Investigator for OHSU study #3912, "A multicenter, open-label study to assess the efficacy and safety of infliximab (Remicade®) therapy in patients with plaque psoriasis who had an inadequate response to etanercept (Enbrel®) (PSUNRISE)"
15. 2008-2009, Principal Investigator for OHSU study #4255, "Investigating the IL-23/IL-17 inflammatory pathway in psoriasis patients receiving Remicade therapy"
16. 2008-2009, Principal Investigator for OHSU study #4128, "A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis"
17. 2008-2011, Principal Investigator for OHSU study #4570, "A phase 3, multicenter, open-label continuation study for moderate to severe chronic plaque psoriasis subjects who completed a preceding psoriasis study with ABT-874"
18. 2008-2009, Principal Investigator for OHSU study #4499, "Phase 2A randomized, double-blind, vehicle-controlled, intra-individual comparison trial assessing safety, toleration, pharmacokinetics and pilot efficacy of 4 weeks treatment with CP-690,550 in chronic plaque psoriasis"
19. 2008-2010, Principal Investigator for OHSU study #4875, "LY2439821 (anti-IL-17 humanized antibody) multiple-dose safety and tolerability study in subjects with psoriasis vulgaris"
20. 2008-2011, Principal Investigator for OHSU study #4760, "Clinical database for patients with psoriasis"
21. 2008-2011, Principal Investigator for OHSU study #4953, "A randomised, placebo-controlled, single- and multiple-dose, dose escalation trial of anti-IL-20 (109-0012) 100 mg/vial in psoriatic subjects, followed by an expansion phase"

22. 2009-2011, Principal Investigator for OHSU study #5363, "ESPIRIT: A 10-year, postmarketing observational registry of Humira® (adalimumab) in adult patients with chronic plaque psoriasis"
23. 2011-2016, Principal Investigator, "A dose-ranging and efficacy study of LY2439821 (an anti-IL-17 antibody) in patients with moderate-to-severe psoriasis"
24. 2011-2013, Principal Investigator, "A randomized, double-blind, placebo-controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after 12 weeks of treatment, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis (ERASURE)"
25. 2011-2012, Sub-Investigator, "A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis"
26. 2011-2012, Sub-Investigator, "A phase 3 multicenter, randomized, double-blind, placebo-controlled, trial of ustekinumab, a fully human anti-IL-12/23p40 monoclonal antibody, administered subcutaneously, in subjects with active psoriatic arthritis (PSUMMIT I)"
27. 2011-2012, Sub-Investigator, "A phase 3 multicenter, randomized, double-blind, placebo-controlled, trial of ustekinumab, a fully human anti-IL-12/23p40 monoclonal antibody, administered subcutaneously, in subjects with active psoriatic arthritis including those previously treated with biologic anti TNFa agent(s) (PSUMMIT II)"
28. 2011-2012, Sub-Investigator, "A multicenter, randomized, double-blind, placebo-controlled evaluation of rosacea-related inflammatory biochemical markers in the skin of adults with papulopustular rosacea treated with daily doxycycline 40 mg (30 mg immediate release/10 mg delayed releases beads) capsules"
29. 2011-2012, Sub-Investigator, "A randomized, double-blind, vehicle-controlled, multicenter, parallel group study of the safety and efficacy of terbinafine nail lacquer 3% in the treatment of mild to moderate distal subungual onychomycosis of the toenails for 52 weeks"
30. 2011-2012, Sub-Investigator, "A randomized, double-blind, vehicle-controlled, multi-center study to evaluate the efficacy and safety of AN2690 topical solution, 5%, vs. solution vehicle in the treatment of onychomycosis of the toenails in adults"
31. 2011-2012, Sub-Investigator, "A multicenter, randomized, double-blind, parallel group study to evaluate the safety and efficacy of bimatoprost solution 0.03%, 0.1%, and 0.3% compared with vehicle in men with androgenic alopecia with an open-label active comparator (minoxidil 5%) group"
32. 2011-2012, Sub-Investigator, "A multicenter, randomized, double-blind, parallel group study to evaluate the safety and efficacy of bimatoprost solution 0.03%, 0.1%, and 0.3% compared with vehicle in women with female pattern hair loss with an open-label active comparator (minoxidil 2%) group"
33. 2011, Sub-Investigator, "A multicenter, double-blind, randomized, placebo-controlled, parallel-group extension study to evaluate the safety and efficacy of

BOTOX (botulinum toxin type A) purified neurotoxin complex in subjects with facial rhytides (crow's feet lines and glabellar lines)"

34. 2011, Sub-Investigator, "A pivotal USA randomized, evaluator-blinded, active controlled, multi-center, split-face comparison study of Emervel Classic Lidocaine versus Juvederm Ultra in the treatment of moderate to severe facial wrinkles and folds"
35. 2011-2017, Principal Investigator, "A multicenter study with a randomized, double blind, placebo-controlled induction dosing period followed by a randomized maintenance dosing period and a log-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe plaque psoriasis "
36. 2011-2013, Sub-Investigator, "An open-label extension study to evaluate the safety of etanercept in pediatric subjects with plaque psoriasis"
37. 2012-2013, Sub-Investigator, "A phase 2 multicenter, randomized, placebo- and active-comparator-controlled, dose-ranging trial to evaluate CNTO 1959 for the treatment of subjects with moderate to severe plaque type psoriasis (X-PLORE)"
38. 2012, Sub-investigator, "A phase II study of photodynamic therapy with Levulan topical solution plus blue light versus Levulan topical solution vehicle plus blue light using spot and broad area application and incubation times of 1, 2 and 3 hours for the treatment of multiple actinic keratoses on the face or scalp"
39. 2012, Sub-investigator, "A double-blind, randomized, parallel-group, vehicle controlled, multicenter study to evaluate the safety and bioequivalence of a generic butenafine HCl cream, 1% and reference listed Lotrimin Ultra (butenafine HCl cream, 1%) and compare both active treatments to a vehicle control in the treatment of interdigital tinea pedis"
40. 2012-2015, Principal Investigator, "A phase 3b, randomized, double-blind, active controlled, multicenter study to evaluate a "subject-tailored" maintenance dosing approach in subjects with moderate-to-severe plaque psoriasis (PSTELLAR)"
41. 2012-2013, Sub-investigator, "A sequential treatment regimen of cryotherapy and Picato (ingenol mebutate) gel, 0.015% field therapy compared to cryotherapy alone for the treatment of actinic keratosis on the face and scalp"
42. 2012-2013, Sub-Investigator, "A randomized, phase 2, double-blind, placebo-controlled trial to evaluate the safety and efficacy of HL-009 liposomal gel in adult patients with mild to moderate atopic dermatitis"
43. 2012-2013, Principal Investigator, "A randomized, double-blind, placebo-controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after 12 weeks of treatment, and to assess the safety, tolerability, usability and long-term efficacy in subjects with chronic plaque-type psoriasis (FEATURE)"
44. 2012-2014, Sub-Investigator, "Safety and efficacy of luliconazole solution, 10% with two dosing regimens in distal subungual onychomycosis of the toenails: a randomized, double-blind, vehicle-controlled, phase 2b/3 study"

45. 2012-2013, Sub-Investigator, "A multicenter, randomized, double-blind, four-week, bilateral study of the safety and efficacy of two concentrations of AN2728 ointment administered once or twice a day in adolescents with atopic dermatitis"
46. 2012-2015, Principal Investigator, "A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab"
47. 2012-2013, Sub-Investigator, "A randomized, double-blind, parallel-group, vehicle-controlled, multicenter study comparing imiquimod cream, 3.75% generic to reference listed drug in the treatment of actinic keratosis of the face or balding scalp"
48. 2012-2019, Principal Investigator, "A 12-week multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2439821 to etanercept and placebo in patients with moderate to severe plaque psoriasis with a long-term extension period"
49. 2012, Sub-Investigator, "A parallel-group, vehicle-controlled, randomized, double-blind study of the efficacy and safety of product 49778 and product 10156 in subjects with seborrheic dermatitis"
50. 2012-2015. Principal Investigator, "A phase 3 study to evaluate the efficacy, safety, and effect of withdrawal and retreatment with brodalumab in subjects with moderate to severe plaque psoriasis: AMAGINE-1"
51. 2012-2013, Sub-Investigator, "An open-label, multicenter study of the efficacy of Cloderm cream (clocortolone pivalate, 0.1%) in the treatment of moderate plaque psoriasis for 28 days"
52. 2013, Sub-Investigator, "Oxymetazoline HCl cream for the treatment of erythema associated with rosacea"
53. 2013-2019, Principal Investigator, "A 52-week, phase 3, randomized, active comparator and placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/MK-3222, followed by an optional long term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis"
54. 2013-2014, Sub-Investigator, "Bimatoprost for the treatment of eyebrow hypotrichosis"
55. 2013, Principal Investigator, "A multicenter, randomized, double-blind, parallel group comparison of halobetasol propionate lotion 0.05% versus vehicle lotion in subjects with plaque psoriasis"
56. 2013-2014, Principal Investigator, "A phase 2B, multi-site, randomized, double-blind, vehicle-controlled, parallel-group study of the efficacy, safety, local tolerability and pharmacokinetics of 2 dose strengths and 2 regimens of tofacitinib ointment in subjects with chronic psoriasis"
57. 2013-2014, Principal Investigator, "A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study investigating the efficacy, safety,

pharmacokinetic and biomarker profiles of REGN668 administered to adult patients with moderate-to-severe atopic dermatitis”

58. 2013, Principal Investigator, “Qualitative interviews for the development of a patient-reported outcome (PRO) measure in patients with seborrheic keratosis (phase I)”
59. 2013-2014, Principal Investigator, “A multicenter, randomized, double-blind, vehicle controlled, parallel group comparison study to determine the therapeutic equivalence of generic imiquimod cream, 2.5% and Zyclara® (imiquimod) cream, 2.5% in subjects with actinic keratoses”
60. 2014, Principal Investigator, “A phase 2, randomized, double-blind, vehicle controlled, dose-ranging study of the effect of DRM04B in subjects with axillary hyperhidrosis”
61. 2014-2015, Principal Investigator, “A phase 2 randomized, double-blind, vehicle controlled, dose-ranging study to investigate the efficacy and safety of ME1111 in patients with mild to moderate onychomycosis”
62. 2014, Sub-Investigator, “Safety and efficacy of bimatoprost solution versus vehicle in men with androgenic alopecia”
63. 2014, Principal Investigator, Efficacy and safety of ingenol mebutate gel 0.06% when applied once daily for 2, 3 or 4 consecutive days to a treatment area of approximately 250 cm² on trunk and extremities in subjects with actinic keratosis: an international, phase 2, randomized, multicentre, double-blind, vehicle-controlled, 8-week trial”
64. 2014, Principal Investigator, “Qualitative interviews for the development of a patient-reported outcome (PRO) measure in patients with seborrheic keratosis (phase II)”
65. 2014-2017 Principal Investigator, “An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab trials”
66. 2014-2015, Principal Investigator, “A 48 week study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-controlled (ustekinumab), double-blind within dose groups of BI 655066)”
67. 2014-2015, Sub-Investigator, “A long-term safety and efficacy study of oxymetazoline HCl cream 1.0% in patients with persistent erythema associated with rosacea”
68. 2014-2016, Principal Investigator, “A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to determine efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis”
69. 2014, Sub-Investigator, “Exploratory genetic study in subjects with moderate to severe psoriasis”
70. 2014, Sub-Investigator, “Efficacy and safety of oxymetazoline HCl cream 1.0% for the treatment of persistent erythema associated with rosacea”

71. 2014, Principal Investigator, "A randomized, double-blind, vehicle-controlled, parallel group study of the dose-response profile of A-101 topical solution in subjects with seborrheic keratosis"
72. 2014-2015, Principal Investigator, "A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira in patients with moderate to severe chronic plaque-type psoriasis"
73. 2014-2015, Principal Investigator, "A randomized, double-blind, placebo-controlled, study investigating vaccine responses in adults with moderate to severe atopic dermatitis treated with dupilumab"
74. 2014-2015, Principal Investigator, "A randomized, double-blind, vehicle-controlled, parallel group study of the dose-response profile of A-101 solution in subjects with seborrheic keratosis of the face"
75. 2014-2016, Principal Investigator, "A randomized, double-blind, placebo-controlled study to demonstrate the efficacy and long-term safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis"
76. 2014-2016, Principal Investigator, "A phase 3, multicenter, randomized, double-blind study to evaluate the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab"
77. 2014-2015, Principal Investigator, "A phase 2, multicenter, randomized, double-blind, vehicle-controlled study on the safety, tolerability, and efficacy of 0.15% and 0.25% concentrations of topical SM04554 solution in male subjects with androgenetic alopecia (AGA)"
78. 2014-2016, Principal Investigator, "A randomized, double-blind, placebo-controlled study of the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum"
79. 2014-2016, Principal Investigator, "A 2-year, open-label, safety extension study of gevokizumab in patients with pyoderma gangrenosum"
80. 2014-2018, Principal Investigator, "A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis"
81. 2014-2020, Principal Investigator, "A phase 3, multicenter, randomized, double-blind placebo and active comparator-controlled study evaluating the efficacy and safety of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis"
82. 2014-2017, Principal Investigator, "An open label extension trial assessing the safety and efficacy of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis"
83. 2015-2017, Principal Investigator, "A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail"

84. 2015, Study Investigator, "A test of seborrheic keratosis physician lesion assessment reliability"
85. 2015, Principal Investigator, "A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis"
86. 2015, Principal Investigator, "A multi-center, double-blind, randomized, vehicle controlled, parallel-group study to compare Perrigo UK FINCO's brimonidine topical gel 0.33% to Mirvaso (brimonidine) topical gel 0.33%, and both active treatments to a vehicle control in the treatment of persistent (non-transient) facial erythema of rosacea"
87. 2015, Principal Investigator, "A multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects"
88. 2015-2016, Principal Investigator, "An open-label phase II study to evaluate the safety of lebrikizumab compared to topical corticosteroids in adult patients with persistent, moderate to severe atopic dermatitis"
89. 2015-2016, Principal Investigator, "A double-blind extension study to evaluate the post-treatment safety and duration of clinical effect of LIPO-202 in subjects who complete either the LIPO-202-CL-18 or LIPO-202-CL-19 study"
90. 2015-2016, Principal Investigator, "A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab dosing regimens in patients with moderate-to-severe plaque psoriasis"
91. 2015-2016, Principal Investigator, "A randomized, double-blind, vehicle-controlled, parallel group study of the safety, tolerability, bioavailability and dose response of ALX-101 topical gel administered twice daily in adult subjects with mild to moderate atopic dermatitis (ALX-101-ATOP-201)"
92. 2015-2016, Principal Investigator, "A phase 3, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of IDP-118 in the treatment of plaque psoriasis (V01-118A-302)"
93. 2015-2016, Principal Investigator, "A phase 3, multicenter, open label study to evaluate the long-term safety of IDP-118 lotion in the treatment of plaque psoriasis (V01-118A-303)"
94. 2015-2018, Principal Investigator, "A phase 3, multicenter, randomized, double-blind, parallel-group, placebo-and-active-controlled study followed by a placebo-controlled maintenance period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis"
95. 2016, Principal Investigator, "A randomized, double-blind, vehicle-controlled, parallel group study of the safety and effectiveness of A-101 solution 40% in subjects with seborrheic keratosis on the trunk, extremities and face (study 2)"
96. 2016-2018, Principal Investigator, "A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with

secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis”

97. 2016-2018, Principal Investigator, “BI 655066 versus ustekinumab and placebo comparators in a randomized double blind trial for maintenance use in moderate to severe plaque type psoriasis (UltIMMa-1)”
98. 2016-2018, Principal Investigator, “BI 655066 versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment (IMMhance)”
99. 2016-2018, Principal Investigator, “A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab versus placebo in patients with moderate-to-severe genital psoriasis”
100. 2016-2018, Principal Investigator, “A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY)”
101. 2016-2017, Principal Investigator, “A phase 2 randomized, double-blind, placebo-controlled, parallel-cohort study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of once-daily application of topical VDA-1102 ointment for 28 days in subjects with actinic keratosis”
102. 2016-2017, Principal Investigator, “A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bimekizumab in adult subjects with moderate-to-severe chronic plaque psoriasis”
103. 2016-2018, Principal Investigator, “A phase 2B, multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate-to-severe chronic plaque psoriasis”
104. 2016-2018, Principal Investigator, “A phase IIA, randomized, double-blind, placebo-controlled study of the safety and efficacy of varying regimens of CANDIN for treatment of common warts (verruca vulgaris)”
105. 2016-2017, Principal Investigator, “Phase 2 study of RVT-501 in adult and adolescent subjects with atopic dermatitis”
106. 2017-2018, Principal Investigator, “A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of mepolizumab administered subcutaneously in subjects with moderate to severe atopic dermatitis”
107. 2017-present, Principal Investigator, “A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS)”
108. 2017-2018, Principal Investigator, “An open-label, randomized, actual use study of dupilumab auto-injector device in patients with atopic dermatitis”

109. 2017-2018, Principal Investigator, "Multicenter, randomized, double-blind, placebo-controlled, phase 2A study of setipiprant tablets in androgenetic alopecia in males with a comparator arm"
110. 2017-2019, Principal Investigator, "A randomized, double-blind, placebo-controlled, parallel group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO)"
111. 2017-2018, Principal Investigator, "A randomized, double-blind, placebo-controlled study to Investigate the efficacy and safety of dupilumab monotherapy in patients >12 to <18 years of age, with moderate-to-severe atopic dermatitis"
112. 2017-2018, Principal Investigator, "An open-label, multi-center trial to assess the safety of single and repeat treatments of daxibotulinumtoxinA for injection for treatment of moderate to severe glabellar lines (SAKURA OPEN LABEL SAFETY)"
113. 2017-2020, Principal Investigator, "A phase IV, open label study of the effects of apremilast on vascular inflammation and cardiometabolic function in psoriasis"
114. 2017-2020, Principal Investigator, "A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy"
115. 2017-2019, Principal Investigator, "An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients >6 months to <18 years of age with atopic dermatitis"
116. 2017-2019, Principal Investigator, "A phase 3, double-blind, vehicle-controlled, randomized, parallel group, multicenter, efficacy and safety study of KX2-391 ointment 1% in adult subjects with actinic keratosis on the face or scalp"
117. 2017-2018, Principal Investigator, "A randomized, double-blind, placebo-controlled, phase 2b, multicenter study to evaluate the safety, efficacy, and tolerability of SNA-120 in subjects with pruritus associated with psoriasis vulgaris"
118. 2017-2018, Sub-Investigator, A phase 2b/3 randomized, double-blind, placebo-controlled, parallel group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer's dementia"
119. 2018, Principal Investigator, "Randomized, double-blind, vehicle-controlled, multicenter, parallel-group, phase 2a study to assess the safety and efficacy of PR022 topical gel in adults with mild to moderate atopic dermatitis"
120. 2018-2020, Principal Investigator, "A phase 3, multicenter, study with an active-controlled initial treatment period followed by a dose-blind maintenance treatment period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis"
121. 2018-2020, Principal Investigator, "A phase 3, multicenter, double-blind, placebo-controlled study with an initial treatment period followed by a randomized-withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis"

122. 2018, Principal Investigator, "Phase 2 study to evaluate the efficacy, safety, and tolerability of RVT-501 topical ointment in pediatric patients with mild to moderate atopic dermatitis"
123. 2018-2019, Principal Investigator, "A randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis"
124. 2018-2019, Principal Investigator, "A multicenter study with a randomized, double-blind, placebo-controlled induction dosing period followed by a randomized withdrawal maintenance dosing period to evaluate the efficacy and safety of mirikizumab in patients with moderate-to-severe plaque psoriasis: OASIS-1"
125. 2018-2020, Principal Investigator, "A multicenter, randomized, open label, efficacy assessor-blinded study of risankizumab compared to secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy"
126. 2018-2019, Sub-Investigator, "A phase 2B open-label study to evaluate the efficacy, safety, and tolerability of topical VDA-1102 ointment in subjects with actinic keratosis"
127. 2018-2020, Principal Investigator, "A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects"
128. 2018-present, Principal Investigator, "A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis"
129. 2018-present Principal Investigator, "A phase 3 multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis"
130. 2018-2022 Principal Investigator, "An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials"
131. 2018-present, Principal Investigator, "A multicenter, randomized, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis"
132. 2018-present, Principal, Investigator, "A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis"
133. 2018-2019, Principal Investigator, "A randomized, double-blind, placebo-controlled multicenter study to evaluate the safety, tolerability and efficacy of ATI-501 oral suspension compared to placebo in adult subjects with alopecia areata, alopecia universalis, or alopecia totalis"
134. 2018-2020, Sub-Investigator, "A phase 2, multicenter, randomized, placebo-controlled, double-blind, proof-of-concept study to evaluate guselkumab for the treatment of subjects with moderate to severe hidradenitis suppurativa"

135. 2018-2020, Principal Investigator, "A 24-week multicenter, randomized, double-blind, parallel-group study comparing the efficacy and safety of ixekizumab to guselkumab in patients with moderate-to-severe plaque psoriasis"
136. 2018-2021, Principal Investigator, "A multicenter, long-term extension to evaluate the long-term safety and maintenance of treatment effect of mirikizumab in patients with moderate-to-severe plaque psoriasis: OASIS-3"
137. 2019-2021, Sub-Investigator. "A phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of risankizumab in adult subjects with moderate to severe hidradenitis suppurativa"
138. 2019-2020 Sub-Investigator, "Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczema"
139. 2019-2020, Principal Investigator, "A phase 3b multicenter, randomized, double-blind, double-dummy, active controlled study comparing the safety and efficacy of upadacitinib to dupilumab in adult subjects with moderate to severe atopic dermatitis"
140. 2019-2020, Principal Investigator, "A multi-center, randomized, double-blind, placebo- and active comparator-controlled phase 3 study to evaluate the efficacy and safety of BMS-986165 in subjects with moderate-to-severe plaque psoriasis"
141. 2019-present, Principal Investigator, "A multicenter, randomized, double-blind, placebo-controlled, operationally seamless, adaptive phase 2/3 study to evaluate the efficacy and safety of baricitinib in adult patients with severe or very severe alopecia areata"
142. 2019, Principal Investigator, "Open-label study of ATI-502 topical solution for the treatment of alopecia areata, alopecia universalis, and alopecia totalis"
143. 2019-2020, Sub-Investigator, "A phase 3, multi-center, randomized, double-blind, vehicle-controlled, parallel group study comparing the efficacy and safety of SB206 and vehicle gel once daily in the treatment of molluscum contagiosum"
144. 2019-2020, Sub-Investigator, "A phase 3 efficacy and safety study of tapinarof for the treatment of plaque psoriasis in adults"
145. 2019-2021, Sub-Investigator, "A long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults"
146. 2019-2021, Principal Investigator, "A phase 3, double-blind, randomized, 8-week, vehicle-controlled efficacy and safety study of ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis"
147. 2019-2022, Principal Investigator, "A multicenter, randomized, double-blind, placebo-controlled clinical study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe plaque psoriasis of the scalp"
148. 2019-2022, Principal Investigator, "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrakizumab in patients with moderate-to-severe atopic dermatitis"

149. 2019-2021, Principal Investigator, "A phase 3, double-blind, randomized, vehicle-controlled, efficacy and safety study of ruxolitinib cream followed by an extension period in participants with vitiligo"
150. 2020-present, Principal Investigator, "An open-label, multi-center extension study to characterize the long-term safety and efficacy of BMS-986165 in subjects with moderate-to-severe plaque psoriasis"
151. 2020-present, Principal Investigator, "A phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in study M16-046"
152. 2020-2022, Principal Investigator, "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in patients with moderate-to-severe atopic dermatitis"
153. 2020-2022, Principal Investigator, "A phase 3B randomized, double-blind, double-dummy, active controlled multi-center study assessing the efficacy and safety of abrocitinib compared with dupilumab in adult participants on background topical therapy with moderate to severe atopic dermatitis"
154. 2020-present, Principal Investigator, "A phase 3 open-label, multi-center, long-term study investigating the safety and efficacy of PF-06651600 in adult and adolescent participants with alopecia areata"
155. 2020-2022, Sub-Investigator, "A proof of concept study to evaluate the efficacy, safety, and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled with topical therapies-PRELUDE"
156. 2020-2022, Sub-Investigator, "A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-cohort, dose-ranging study investigating the effect of EDP1815 in the treatment of mild to moderate plaque psoriasis"
157. 2020-2022, Principal Investigator, "A double-blind, vehicle-controlled, randomized withdrawal and treatment extension study to assess the long-term efficacy and safety of ruxolitinib cream in participants with vitiligo"
158. 2020-present, Principal Investigator, "A long-term study to assess the safety and efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis"
159. 2021-2022, Principal Investigator, "A phase 3, multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 654 compared with ustekinumab in subjects with moderate to severe plaque psoriasis"
160. 2021-present, Principal Investigator, "A multicenter, randomized, double-blinded study evaluating the pharmacokinetics, efficacy and safety of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in subjects with moderate to severe plaque psoriasis"
161. 2021-2022, Principal Investigator, "A phase 3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of lebrikizumab on vaccine responses in adult patients with moderate-to-severe atopic dermatitis"

162. 2021-present, Principal Investigator, "A phase 3, 4-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-151 cream 0.15% administered QD in subjects with atopic dermatitis"
163. 2021-present, Principal Investigator, "A phase 3, multicenter, open-label extension study of the long-term safety of ARQ-151 cream 0.15% and ARQ-151 cream 0.05% in subjects with atopic dermatitis"
164. 2021-present, Principal Investigator, "A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study of the efficacy and safety of INCB054707 followed by an extension period in participants with vitiligo"
165. 2021-present, Principal Investigator, "A phase 2, multicenter, global, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of cendakimab (CC-93538) in adult subjects with moderate to severe atopic dermatitis"
166. 2021-present, Principal Investigator, "A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety and efficacy of upadacitinib in subjects with non-segmental vitiligo"
167. 2021-present, Principal Investigator, "A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata"
168. 2021-present, Sub-Investigator, "A phase 3 efficacy and safety study of tapinarof for the treatment of moderate to severe atopic dermatitis in children and adults"
169. 2021-2022, Principal Investigator, "A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-154 foam 0.3% administered QD in subjects with seborrheic dermatitis (STRATUM)"
170. 2021-2022, Principal Investigator, "A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-154 foam 0.3% administered QD in subjects with scalp and body psoriasis (ARRECTOR)"
171. 2022-present, Sub-Investigator, "A phase 2, multicenter, double-blind, placebo-controlled, multiple-cohort study investigating the effect of EDP1815 in participants for the treatment of mild, moderate and severe atopic dermatitis"
172. 2022-present, Principal Investigator, "A multicenter, open-label, extension study to assess the long-term safety and efficacy of CTP-543 in adult patients with moderate to severe alopecia areata"
173. 2022-present, Principal Investigator, "Decreasing resident memory T cells while increasing clinical durability: higher induction doses of risankizumab for moderate-to-severe plaque psoriasis (KNOCKOUT)," NCT05283135
174. 2022-present, Sub-Investigator, "A phase 2b pivotal study to evaluate the efficacy and safety of izokibep in subjects with moderate to severe hidradenitis suppurativa"
175. 2022-present, Principal Investigator, "A phase IIb, randomised, double-blind, placebo-controlled, parallel group, multicentre dose ranging study of a subcutaneous anti-OX40L monoclonal antibody (KY1005) in moderate to severe atopic dermatitis"

176. 2022-present, Sub-Investigator, "A long-term extension trial in participants with atopic dermatitis who participated in previous phase 2 and 3 EDP1815 trials"
177. 2022-present, Principal Investigator, "A phase 3, multicenter, open-label, single-arm study to evaluate the safety and tolerability of tirbanibulin ointment 1% applied to a field of approximately 100 cm² on the face or balding scalp in adult patients with actinic keratosis"
178. 2022-present, Principal Investigator, "A randomized, vehicle-controlled, safety and efficacy study of EV101 in adult subjects with atopic dermatitis"
179. 2022-present, Principal Investigator, "A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ESK-001 in patients with moderate to severe plaque psoriasis"
180. 2022-present, Principal Investigator, "A phase 3B/4, multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of deucravacitinib in participants with moderate-to-severe scalp psoriasis (PSORIATYK SCALP)"
181. 2022-present, Sub-Investigator, "A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of lirentelimab in adult subjects with H-1 antihistamine refractory chronic spontaneous urticaria"
182. 2022-present, Principal Investigator, "A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of VTX958 in participants with moderate to severe psoriasis"
183. 2023-present, Sub-Investigator, "A phase 3, double-blind, randomized, placebo-controlled, efficacy and safety study of povorcitinib (INCB054707) in participants with moderate to severe hidradenitis suppurativa"
184. 2023-present, Sub-Investigator, "A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate clinical efficacy and safety of deucravacitinib (BMS-986165) in participants with alopecia areata"
185. 2023-present, Sub-Investigator, "A phase 3b/4 randomized, open-label, efficacy assessor blinded study, comparing the safety and assessor blinded efficacy of upadacitinib to dupilumab in subjects with moderate to severe atopic dermatitis (Level-Up)"

Research Grants:

1. 1989-1993, "Intralesional Cyclosporine for Alopecia Totalis," Principal Investigator, Alopecia Areata Foundation Research Grant, \$15,000
2. 1996-2004, "Immunologic and virologic studies of the skin with particular relevance to HIV disease and Kaposi's sarcoma pathogenesis," continual NIH intramural funding with increasing yearly budgets based upon outstanding evaluations by internal and external review panels
3. 1998-2000, "Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis," Principal Investigator, NCI Division of Clinical Sciences Intramural Research Award, \$100,000/year
4. 1999-2006, "Topical Agents to Prevent Mucosal HIV Transmission," Co-Investigator, NIH extramural Program Project #AI51649

5. 2000-2002, "Novel Transgenic Mouse Models of Kaposi's Sarcoma," Principal Investigator, NCI Division of Clinical Sciences Intramural Research Award, \$75,000/year
6. 2004, "Topical Agents to Prevent Mucosal HIV Transmission," Principal Investigator, James B. Pendleton Charitable Trust, \$75,400
7. 2005-2006 "Efalizumab for Moderate to Severe Atopic Dermatitis- A Phase I Pilot Study in Adults," Principal Investigator for laboratory-based studies, Genentech, \$25,000
8. 2006-2007, "The Role of IL-23 in the Pathogenesis of Psoriasis," Principal Investigator, National Psoriasis Foundation Research Grant, \$30,000
9. 2006-2007, "Psoriasis as a T IL-17 Autoimmune Skin Disease?" Principal Investigator, Oregon Medical Research Foundation, \$30,000
10. 2007-2010, "Psoriasis-like Disease Induced by TGFb1 and IL-23," Principal Investigator, Veterans Affairs Merit Award, \$375,000
11. 2007, "Psoriasis-like Disease Induced by IL-23," Principal Investigator, American Skin Association, \$15,000
12. 2007-2009, "Role of IL-23 in Psoriasis Pathogenesis," Principal Investigator, National Institutes of Health 1 R21 AR054495-01A1, \$275,000
13. 2008-2009, "Investigating the IL-23/IL-17 Inflammatory Pathway in Psoriasis Patients Receiving Remicade Therapy," Principal Investigator, Centocor, \$67,400
14. 2008-2009, "Psoriasis fellow support," Principal Investigator, Abbott, \$45,000
15. 2009-2011, "Trim32 Regulation of Piasy in Skin Homeostasis," Co-investigator (3% effort), National Institutes of Health R01 AR055651
16. 2009-2011, "Training in the Molecular Basis of Skin/Mucosa Pathobiology," Associate Program Director, National Institutes of Health T32 CA106195-06A1
17. 2009-2011, "Comparative Effectiveness of Biologics for Psoriasis," Steering Committee Member, National Institutes of Health RC1 ARO58204
18. 2009-2010, "Candida albicans as a potential immunologic trigger for psoriasis," Principal Investigator, Oregon Medical Research Foundation, \$40,000
19. 2011-2016, "HIV-1 R5 Envelope Determinants and Properties that Affect Transmission," Significant Contributor, National Institutes of Health R01
20. 2020, "Decreasing resident memory T cells while increasing clinical durability: higher induction doses of risankizumab for moderate-to-severe plaque psoriasis," Principal Investigator, National Psoriasis Foundation, Milestones to a Cure

Consulting Activities:

2003, Consultant, FDA Center for Drug Evaluation and Research
 2004, Scientific Consultant, Genentech
 2004-2007, Medical Advisory Board, Coria Laboratories, Ltd.
 2005-present, Scientific Advisory Board, Maui Derm annual meeting
 2005-2008, Consultant, MEDACorp
 2005-present, Scientific Consultant, Centocor, Inc./Janssen
 2005-2008, Dermatology National Faculty Speaker's Bureau, Centocor, Inc.
 2006-2011, Scientific Consultant, Anacor Pharmaceuticals

2006-2008 Member, The Society of Industry Leaders
2006-present, Scientific Consultant, Speaker Board Abbott Laboratories, Inc./AbbVie
2006-2008, Speaker Board, Abbott Laboratories, Inc.
2006-2008, Speaker Board, Amgen
2006-2008, Member, Medical Education Speakers Network
2007, Consultant, CVS Pharmacy
2007, Medical Consultant, Barrier Therapeutics, Inc.
2007, Medical Consultant, Emeritus Educational Sciences
2007, Scientific Consultant, CombinatoRx
2007, Scientific Consultant, Cerimon Pharmaceuticals
2007-present, Scientific Consultant, Eli Lilly and Company
2007-2010, Scientific Consultant, MacroGenics, Inc.
2008, Scientific Consultant, PM Toleikis & Associates Consulting, Inc.
2008-present Scientific Consultant, Amgen
2008, Scientific Consultant, Vascular Biogenics, Ltd.
2008-2013, Invited Member, Scientific Steering Committee for phase 4 PSUNRISE study, Centocor
2009-2011, Invited Member, Scientific Steering Committee for phase 4 ESPRIT study, Abbott
2010-2012, Scientific Consultant, Takeda Pharmaceuticals
2010, Scientific Consultant, Artielle Immunotherapeutics
2010-2012, Invited Key Informant, Federal Advisory Panel of the Agency for Healthcare Research and Quality on "Biologic and Non-biologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis"
2010-2019, Invited Member, Scientific Steering Committee for phase 3 secukinumab psoriasis studies, Novartis
2010-present, Scientific Consultant, Novartis
2010-present, Scientific Consultant, Speaker Board, Pfizer
2010-present, Scientific Consultant, Boehringer Ingelheim
2011-present, Medical Advisor, Ultra
2011-2016, Invited Lead Member, Scientific Steering Committee for phase 3B PSTELLAR study, Janssen
2012-2019, Dermatology National Faculty Speaker's Bureau, Janssen
2012, Scientific Consultant, Maruho
2012-2018, Scientific Consultant, Allergan
2013-present, Scientific Consultant, Regeneron/Sanofi
2013-present, Invited Member, Lilly Autoimmune Strategic Advisory Board
2013-present, Invited Member, Lilly Global Advisory Board for ixekizumab
2013, Scientific Consultant, Baxter
2013-2017, Scientific Consultant, Merck
2013, Scientific Consultant, Momenta
2013-2018, Scientific Consultant, Celgene
2014-present, Invited Member, Scientific Steering Committee for phase 3 guselkumab psoriasis studies, Janssen

2014, Scientific Consultant, Samumed
2014-present, Scientific Consultant, Galderma
2015-2019, Invited Member, Scientific Steering Committee for phase 3 BI 655066 psoriasis studies, Boehringer Ingelheim
2015-2019, Invited Member, Publication Committee for phase 3 BI 655066 psoriasis studies, Boehringer Ingelheim
2015-2020 Scientific Consultant, Dermira
2015-2018 Scientific Consultant, Genentech
2015-present, Chair, Efficacy Subcommittee, Lilly Global Medical Education Steering Committee
2016-present, Lilly National Speaker Board
2016-2019, Scientific Consultant, Valeant
2016-2019, Scientific Consultant, MedImmune/AstraZeneca
2016-present, Scientific Consultant, UCB
2016-present, Scientific Consultant, Sun Pharma
2016-present, Scientific Consultant, Sandoz
2016-2019, Scientific Consultant, Gilead
2017-2019, Scientific Consultant, Purdue Pharma
2017-2019, Scientific Consultant, Roivant Sciences
2017-present, Scientific Consultant, Almirall
2017-2019, Scientific Consultant, 23andMe
2017-2019, Scientific Consultant, Vidac
2017-2018, Scientific Consultant, Sienna Pharmaceuticals
2017-present, Regeneron/Sanofi Genzyme National Speaker Board
2017-present, Scientific Consultant, Meiji
2018-present, Scientific Consultant, Akros
2018-present, Scientific Consultant, Arena
2018-present, Scientific Consultant, National Multidisciplinary Immunology Board, Speaker Board, Bristol-Myers Squibb
2019-present, Scientific Consultant, FLX Bio
2019-present, Speaker Board, AbbVie
2019-present, Scientific Consultant, Forte
2019-present, Scientific Consultant, Serono
2020-present, Scientific Consultant, Rapt
2020-present, Scientific Consultant, Incyte
2020-present, Scientific Consultant, Aligos
2021-present, Scientific Consultant, Landos
2021-present, Scientific Consultant, Aslan
2021-present, Scientific Consultant, Vibliome
2021-present, Scientific Consultant, EcoR1
2021-present, Scientific Consultant, Xencor
2022-present, Scientific Consultant, AnaptysBio
2022-present, Scientific Consultant, Q32 Bio
2022-present, Scientific Consultant, Alumis

2022-present, Scientific Consultant, Union
2022-present, Scientific Consultant, Aclaris
2022-present, Scientific Consultant, Microbion

Mentorship:

- Primary mentor to 9 laboratory research-based postdoctoral fellows (2 with Ph.D.: Drs. J. Paul Zoetewey, Erin Harper; 2 with M.D.: Drs. Nickolai Talanin, Andrea Niedermeier; and 5 with M.D., Ph.D.: Drs. Tatsuyoshi Kawamura, Takahiro Watanabe, Makoto Sugaya, Wei Liao, Shinji Kagami)
 - 4 currently in independent academic positions, with 2 in chairman positions (Drs. Kawamura, Sugaya, Niedermeier, Liao)
 - 2 currently in industry (Drs. Zoetewey and Harper)
 - 3 currently in private practice dermatology (Drs. Watanabe, Talanin, Kagami)
- Mentor to 8 clinical research-based postdoctoral fellows (7 with M.D.: Drs. Alexa Kimball, Allison Ehrlich, Edward Cowen, Gretchen Vanderbeek, Jennifer Lee, Aman Samrao, Brian Truong, Alison Uyemura)
 - 4 currently in independent academic positions, with 3 in chair/leadership positions (Drs. Kimball, Ehrlich, Cowen, Samrao)
 - 4 currently in private practice (Drs. Vanderbeek, Lee, Truong, Uyemura)
- Primary mentor to 10 students performing laboratory research before or during medical/graduate school
 - 3 went on to train in dermatology and currently in independent academic positions (Drs. Sharon Jacob, Aparche Yang, and Erin Foster)
 - 4 went on to train in dermatology and currently in private practice dermatology (Drs. April Atkins, Stacey Reed, Sam Bremmer, and Ryan Sells)
 - 1 went on to train in medical oncology and currently in private practice (Dr. Krupali Tejura)
 - 2 completed PhDs (Drs. Iliyana Mikell and Heather Rizzo)

Honors/Awards:

1980, Phi Eta Sigma (Freshmen Engineering Honor Society)
1983, Eta Kappa Nu (Electrical Engineering Honor Society)
1983, Tau Beta Pi (Engineering Honor Society)
1983, Golden Key (Leadership Honor Society)
1983, Mortar Board (Leadership Honor Society)
1984, Mortar Board Graduate Fellowship
1988, Alpha Omega Alpha
1992, University of Miami George Ioannides Award for Excellence in Resident Teaching
1996, American Academy of Dermatology Young Investigator in Dermatology Award
1999, U.S. Public Health Service Outstanding Service Medal
2000, Invited participant for "The Biology of HIV Transmission" NIH Think Tank

2001, Invited participant for “Antigen Presenting Cells in HIV Pathogenesis and Therapy” NIH Think Tank

2004, Elected member, American Society for Clinical Investigation

2007, Elected member, American Dermatological Association

2007, OHSU Department of Dermatology Faculty Award for Teaching

2007, OHSU Rose Award for Outstanding Service Excellence by a patient, visitor, or colleague

2008, National Psoriasis Foundation Certificate of Appreciation for outstanding advocacy service to the psoriasis community

2008, OHSU Department of Medicine Career Teaching Achievement Award

2008, University of Massachusetts John R. Person Lecturer in Dermatology

2008, University of Washington Robert Pommerening Lecturer in Dermatology

2011, Dermatology Nurses’ Association First Annual Robin Weber Memorial Immunology Lecture

2011, OHSU Department of Dermatology Faculty Award for Teaching

2011, Invited Councilor, International Psoriasis Council

2012, University of Toronto Ricky K. Schachter Lecturer in Psoriasis

2013, Invited member, Noah Worcester Dermatological Society

2017, University of Cincinnati Smith H. & Lucille Gibson, M.D., Endowed Lecture in Dermatology

2017, Volunteer of the Year, International Psoriasis Council

2019, Invited Councilor, International Eczema Council

2021, National Psoriasis Foundation Recognition Award

2021, Santa Barbara Dermatology Meeting, Keynote Lecture

2021, Highly Cited Researchers list

2022, Board of Directors, International Psoriasis Council

2022, Highly Cited Researchers list

2023, Pillars of Dermatology award

Bibliography:

1. Ellis CN, Pennes DR, Hermann RC, Blauvelt A, Martel W, Voorhees JJ. Long-term radiographic follow-up after isotretinoin therapy. **J Am Acad Dermatol** 1988;18:1252-1261.
2. Kareti LR, Katlein S, Siew S, Blauvelt A. Angiosarcoma of the adrenal gland. **Arch Pathol Lab Med** 1988;112:1163-1165.
Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. **J Am Acad Dermatol** 1991;24:703-705.
3. Blauvelt A, Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. **Arch Dermatol** 1991;127:1159-1166.
4. Blauvelt A, Kerdel FA. Intravenous corticosteroids for systemic mastocytosis. **Arch Dermatol** 1991;127:1586.
5. Zhu WY, Blauvelt A, Goldstein BA, Leonardi CL, Penneys NS. Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated in vitro with liquid nitrogen, trichloroacetic acid, and podophyllin. **J Am Acad Dermatol** 1992;26:710-714.
6. Nahass GT, Blauvelt A, Leonardi CL, Penneys NS. Basal cell carcinoma of the scrotum: report of three cases and review of the literature. **J Am Acad Dermatol** 1992; 26:574-578.
7. Blauvelt A, Kerdel FA. Cutaneous cryptococcosis mimicking Kaposi's sarcoma as the presenting sign of disseminated disease. **Int J Dermatol** 1992;31:279-280.
8. Blauvelt A, Harris HR, Hogan DJ, Jimenez-Acosta F, Ponce I, Pardo RJ. Porphyria cutanea tarda and human immunodeficiency virus infection. **Int J Dermatol** 1992;31:474-479.
9. Blauvelt A, Duarte AM, Pruksachatkunakorn C, Leonardi CL, Schachner LA. Human papillomavirus type 6 infection involving cutaneous nongenital sites. **J Am Acad Dermatol** 1992;27:876-879.
10. Nahass GT, Blauvelt A, Penneys NS. Metastases from basal cell carcinoma of the scrotum. **J Am Acad Dermatol** 1992;26:509-510.
11. Blauvelt A, Duarte AM, Schachner LA. Pool palms. **J Am Acad Dermatol** 1992;27:111.
12. Zhu WY, Leonardi CL, Blauvelt A, Serfling U, Penneys NS. Human papillomavirus DNA in the dermis of condyloma acuminatum. **J Cutan Pathol** 1993;20:447-450.
13. Penneys NS, Leonardi CL, Cook S, Blauvelt A, Rosenberg S, Eells LD, Konwiser M, Aaronson CM. Identification of Mycobacterium tuberculosis DNA in five different types of cutaneous lesions by the polymerase chain reaction. **Arch Dermatol** 1993;129:1594-1598.
14. Rotman DA, Blauvelt A, Kerdel FA. Widespread primary cutaneous infection with Mycobacterium fortuitum. **Int J Dermatol** 1993;32:512-514.
15. Blauvelt A, Turner ML. Gianotti-Crosti syndrome and human immunodeficiency virus infection. **Arch Dermatol** 1994;130:481-483.
16. Rotman DA, Blauvelt A. Two asymptomatic plaques on the chest of a young woman. **Arch Dermatol** 1994;130:1434-1438.

17. Blauvelt A, Katz SI, Udey MC. Human Langerhans cells express E-cadherin. **J Invest Dermatol** 1995;104:293-296.
18. Blauvelt A, Clerici M, Lucey DR, Steinberg SM, Yarchoan R, Walker R, Shearer GM, Katz SI. Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. **J Immunol** 1995;154:3506-3515.
19. Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. **J Immunol** 1995;154:4851-4856.
20. Blauvelt A, Plott RT, Spooner K, Stearn B, Davey RT, Turner ML. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. **Arch Dermatol** 1995;131:360-361.
21. Blauvelt A, Katz SI. The skin as target, vector, and effector organ in human immunodeficiency virus disease. **J Invest Dermatol** 1995;105:122S-126S.
22. Blauvelt A, Chougnat C, Shearer GM, Katz SI. Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by antiinterleukin (IL)-10 antibodies and IL-12. **J Clin Invest** 1996;97:1550-1555.
23. Blauvelt A, Asada H, Klaus-Kovtun V, Altman DJ, Lucey DR, Katz SI. Interleukin-15 mRNA is expressed by human keratinocytes, Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. **J Invest Dermatol** 1996;106:1047-1052.
24. Enk CD, Mahanty S, Blauvelt A, Katz SI. UVB induces IL-12 transcription in human keratinocytes in vivo and in vitro. **Photochem Photobiol** 1996;63:854-859.
25. Blauvelt A. Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda. **Arch Dermatol** 1996;132:1503-1504.
26. Orenstein JM, Alkan S, Blauvelt A, Jeang KT, Weinstein MD, Ganem D, Herndier B. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. **AIDS** 1997;11:F35-F45.
27. Blauvelt A, Sei S, Cook PM, Schulz TF, Jeang KT. Human herpesvirus 8 infection occurs following adolescence in the United States. **J Infect Dis** 1997;176:771-774.
28. Blauvelt A, Asada H, Saville MW, Klaus-Kovtun V, Altman DJ, Yarchoan R, Katz SI. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. **J Clin Invest** 1997;100:2043-2053.
29. Blauvelt A, Herndier BG, Orenstein JM. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. **N Engl J Med** 1997;336:1837-1838.
30. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, Manischewitz J, Golding H. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. **Nat Med** 1997;3:1369-1375.
31. Blauvelt A. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. **Am J Med** 1997;102:16-20.
32. Majors MJ, Berger TG, Blauvelt A, Smith KJ, Turner ML, Cruz PD. HIV-related eosinophilic folliculitis: a panel discussion. **Sem Cutan Med Surg** 1997;16:219-223.

33. Zoetewey JP, Golding H, Mostowski H, Blauvelt A. Cutting edge: cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells. **J Immunol** 1998;161:3219-3223.
34. Cohen SS, Weinstein MD, Herndier BG, Anhalt GJ, Blauvelt A. No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. **J Invest Dermatol** 1998;111:781-783.
35. Duarte AM, Perez JL, Blauvelt A, Schachner LA. Ki-1 (CD30) positive anaplastic large cell lymphoma in childhood. **Int Pediatr** 1998;13:232-234.
36. Zoetewey JP, Blauvelt A. HIV-dendritic cell interactions promote efficient viral infection of T cells. **J Biomed Sci** 1998;5:253-259.
37. Blauvelt A. Langerhans Cells. In: **Encyclopedia of Immunology, Second Edition**. Delves PJ, Roitt IM, Eds. Academic Press Ltd., London. 1998, 1528-1532.
38. Asada H, Klaus-Kovtun V, Golding H, Katz SI, Blauvelt A. Human herpesvirus 6 infects dendritic cells and suppresses human immunodeficiency virus type 1 replication in coinfecting cultures. **J Virol** 1999;73:4019-4028.
39. Zoetewey JP, Eyes ST, Orenstein JM, Kawamura T, Wu L, Chandran B, Forghani B, Blauvelt A. Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. **J Virol** 1999;73:5894-5902.
40. Chougnet C, Cohen SS, Kawamura T, Landay AL, Kessler HA, Thomas E, Blauvelt A, Shearer GM. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. **J Immunol** 1999;163:1666-1673.
41. Papadopoulos EJ, Sasseti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, Saraf MA, Schall T, Blauvelt A, Rosen SD, Hwang ST. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. **Eur J Immunol** 1999;29:2551-2559.
42. Anderson HA, Bergstralh DT, Kawamura T, Blauvelt A, Roche PA. Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen processing compartments. **J Immunol** 1999;163:5435-5443. 246.
43. Blauvelt A. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. **Adv Dermatol** 1999;14:167-207.
44. Blauvelt A. Mucocutaneous Manifestations of the Non-HIV-Infected Immunosuppressed Host. In: **Fitzpatrick's Dermatology in General Medicine, Fifth Edition**. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, Eds. McGraw-Hill, Inc., New York. 1999, 1434-1447.
45. Blauvelt A. Cutaneous Diseases. In: **Handbook of Pediatric HIV Care, First Edition**. Zeichner SL, Read JS, Eds. Lippincott Williams & Wilkins, Philadelphia. 1999, 321-435.
46. Lehrnbecher T, Foster CB, Zhu S, Venzon D, Steinberg SM, Wyvill K, Metcalf JA, Cohen SS, Kovacs J, Yarchoan R, Blauvelt A, Chanock SJ. Variant genotypes of FcR3 influence the development of Kaposi's sarcoma in HIV-infected men. **Blood** 2000;95:2386-2390.

47. Blauvelt A, Glushakova S, Margolis LB. HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. **AIDS** 2000;14:647-651.
48. Wu SJL, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS. Human skin Langerhans cells are targets of dengue virus infection. **Nat Med** 2000;6:816-820.
49. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. **Blood** 2000;96:2562-2567.
50. Orenstein JM, Ciufo DM, Zoetewij JP, Blauvelt A, Hayward GS. Morphogenesis of HHV8 in primary human dermal microvascular endothelium and primary effusion lymphomas. **Ultrastruct Pathol** 2000;24:291-300.
51. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. **J Exp Med** 2000;192:1491-1500.
52. Blauvelt A, Cobb MW, Turner ML. Widespread cutaneous vascular papules associated with peripheral blood eosinophilia and prominent inguinal lymphadenopathy. **J Am Acad Dermatol** 2000;43:698-700.
53. Kawamura T, Qalbani M, Thomas EK, Orenstein JM, Blauvelt A. Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF- β 1 and increased viral replication with CD40 ligand-induced maturation. **Eur J Immunol** 2001;31:360-368.
54. Zoetewij JP, Moses AV, Rinderknecht AS, Davis DA, Overwijk WW, Yarchoan R, Orenstein JM, Blauvelt A. Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. **Blood** 2001;97:2374-2380.
55. Davis DA, Rinderknecht AS, Zoetewij JP, Aoki Y, Read-Connole EL, Tosato G, Blauvelt A, Yarchoan R. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. **Blood** 2001;97:3244-3250.
56. Blauvelt A. Skin diseases associated with human herpesvirus 6, 7, and 8 infection. **J Invest Dermatol Symp Proc** 2001;6:197-202.
57. Zoetewij JP, Rinderknecht AS, Davis DA, Yarchoan R, Blauvelt A. Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines. **J Med Virol** 2002;66:378-383.
58. Zaitseva M, Kawamura T, Loomis R, Goldstein H, Blauvelt A, Golding H. Stromal-derived factor 1 expression in the human thymus. **J Immunol** 2002;168:2609-2617.
59. Watanabe T, Kawamura T, Jacob SE, Aquilino EA, Orenstein JM, Black JB, Blauvelt A. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. **J Invest Dermatol** 2002;119:793-797.

60. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. **J Am Acad Dermatol** 2002;47:512-518.
61. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, Vogel JC, Steinberg SM, Turner ML, Blauvelt A. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. **Arch Dermatol** 2002;138:1341-1346.
62. Rubenstein DS, Blauvelt A, Chen SC, Darling TN. The future of academic dermatology in the United States: report on the resident retreat for future physician-scientists, June 15-17, 2001. **J Am Acad Dermatol** 2002;47:300-303.
63. Blauvelt A. In "that" issue. **J Invest Dermatol** 2002;119:1.
64. Piguet V, Blauvelt A. Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. **J Invest Dermatol** 2002;119:365-369.
65. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA, Kawamura T, Blauvelt A, Arts EJ. Comparing the *ex vivo* fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. **J Virol** 2003;77:1021-1038.
66. Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. **J Immunol** 2003;170:4260-4266.
67. Watanabe T, Sugaya M, Atkins AM, Aquilino EA, Yang A, Borris DL, Brady J, Blauvelt A. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. **J Virol** 2003;77: 6188-6196.
68. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt A. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. **Proc Natl Acad Sci U S A** 2003;100:8401-8406.
69. Blauvelt A, Hwang ST, Udey MC. Allergic and immunologic diseases of the skin. **J Allergy Clin Immunol** 2003;111:560-570.
70. Toro JR, Sanchez S, Turiansky G, Blauvelt A. Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. **Dermatol Clin** 2003;21:301-309.
71. Blauvelt A. Mucocutaneous Manifestations of the Non-HIV-Infected Immunosuppressed Host. In: **Fitzpatrick's Dermatology in General Medicine, Sixth Edition**. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Eds. McGraw-Hill, Inc., New York. 2003, 1152-1164.
72. Blauvelt A. In this issue. **J Invest Dermatol** 2003;121:vi.
73. Sugaya M, Lore K, Koup RA, Douek DC, Blauvelt A. HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. **J Immunol** 2004;172:2219-2224.
74. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, Brennan PJ,

- Belisle JT, Blauvelt A, Porcelli SA, Modlin RL. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. **J Clin Invest** 2004;113:701-708.
75. Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. **J Virol** 2004;78:7602-7609.
76. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. **Science** 2004;306:485-487.
77. Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, Turner ML, Blauvelt A. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. **J Am Acad Dermatol** 2004;50:533-540.
78. Blauvelt A, Bernhard J. Rapid publication for selected JAAD articles. **J Am Acad Dermatol** 2004;50:299-300.
79. Blauvelt A. Kaposi's sarcoma-associated herpesvirus. Yale University/Fujisawa Healthcare, Inc. **Lecture Series in Dermatology** 2004;10:1-24.
80. Blauvelt A. In this issue-full court press on psoriasis. **J Invest Dermatol** 2004;123:viiviii.
81. Sugaya M, Watanabe T, Yang A, Starost MF, Kobayashi H, Atkins AM, Borris DL, Hanan EA, Schimel D, Bryant MA, Roberts N, Skobe M, Staskus KA, Kaldis P, Blauvelt A. Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. **Blood** 2005;105:2356-2363.
82. Blauvelt A. Cutaneous Diseases. In: **Textbook of Pediatric HIV Care**. Zeichner SL, Read JS, Eds. Cambridge University Press, Cambridge. 2005, 413-430.
83. Kawamura T, Kurtz SE, Blauvelt A, Shimada S. The role of Langerhans cells in sexual transmission of HIV-1. **J Dermatol Sci** 2005;40:147-155.
84. Klase Z, Donio MJ, Blauvelt A, Marx PA, Jeang KT, Smith SM. A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames. **Retrovirology** 2006;3:1.
85. Niedermeier A, Talanin N, Chung EJ, Sells RE, Borris DL, Orenstein JM, Trepel JB, Blauvelt A. Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. **J Invest Dermatol** 2006;126:2516-2524.
86. Sugaya M, Fang L, Cardones AR, Kakinuma T, Jaber SH, Blauvelt A, Hwang ST. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. **J Immunol** 2006;177:7665-7672.
87. Ehrlich A, Koch T, Amin B, Liewehr DJ, Steinberg SM, Turner ML, Blauvelt A. Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype. **J Am Acad Dermatol** 2006;54:987-991.e9.
88. Blauvelt A. Cutaneous Diseases. In: **Handbook of Pediatric HIV Care, Second**

- Edition.** Zeichner SL, Read JS, Eds. Cambridge University Press, Cambridge. 2006, 473-502.
89. Sugaya M, Hartley O, Root MJ, Blauvelt A. C34, a membrane fusion inhibitor, blocks HIV infection of Langerhans cells and viral transmission to T cells. **J Invest Dermatol** 2007;127:1436-1443.
 90. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E. Efalizumab for severe atopic dermatitis: a pilot study in adults. **J Am Acad Dermatol** 2007;56:222-227.
 91. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF- β 1. **Expert Rev Dermatol** 2007;2:69-78.
 92. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. **Curr Rheumatol Rep** 2007;9:461-467.
 93. Harper EG, Simpson EL, Takiguchi RH, Boyd MD, Kurtz SE, Bakke AC, Blauvelt A. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. **J Invest Dermatol** 2008;128:1173-1181.
 94. Kawamura T, Koyanagi Y, Nakamura Y, Ogawa Y, Yamashita A, Iwamoto T, Ito M, Blauvelt A, Shimada S. Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. **J Immunol** 2008;180:3297-3304.
 95. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). **Lancet** 2008;371:1675-1684.
 96. White KP, Zedek DC, White WL, Simpson EL, Hester E, Morrison L, Lazarova Z, Liu D, Scagliarini A, Kurtz SE, White CR, Yancey KB, Blauvelt A. Orf-induced immunobullous disease: a distinct autoimmune blistering disorder. **J Am Acad Dermatol** 2008;58:49-55.
 97. Kauls L, Blauvelt A. Skin Disease in Acute and Chronic Immunosuppression. In: **Fitzpatrick's Dermatology in General Medicine, Seventh Edition**. Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Eds. The McGraw-Hill Companies, Inc., New York. 2008, 267-278.
 98. Blauvelt A. Pityriasis Rosea. In: **Fitzpatrick's Dermatology in General Medicine, Seventh Edition**. Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Eds. The McGraw-Hill Companies, Inc., New York. 2008, 362-366.
 99. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. **J Invest Dermatol** 2008;128:1064-1067.
 100. Blauvelt A. HIV Disease and AIDS. In: **Clinical and Basic Immunodermatology**. Gaspari AA, Tying SK, Eds. Springer, London. 2008, 323-334.
 101. Ogawa Y, Kawamura T, Kimura T, Ito M, Blauvelt A, Shimada S. Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. **Blood** 2009;113:5157-5166.

102. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, [Blauvelt A](#). Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. **J Invest Dermatol** 2009;129:2175-2183.
103. Fitch EL, Rizzo HL, Kurtz SE, Wegmann KW, Gao W, Benson JM, Hinrichs DJ, [Blauvelt A](#). Inflammatory skin disease in K5.hTGF- β 1 transgenic mice is not dependent upon the IL-23/Th17 inflammatory pathway. **J Invest Dermatol** 2009;129:2443-2450.
104. Lillis JV, Ansdell VE, Ruben K, Simpson EL, Tumbaga G, Ansdell D, Bremmer S, Kurtz SE, White CR, [Blauvelt A](#), Winthrop KL. Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infections among Satowanese islanders. **Clin Infect Dis** 2009;48:1541-1546.
105. [Blauvelt A](#), Bickenbach JR, Kulesz-Martin MF, Bowcock AM. Montagna Symposium 2008: the biologic basis of psoriasis. **J Invest Dermatol** 2009;129:259-260.
106. [Blauvelt A](#). Ustekinumab and ABT-874. In: **Moderate-to-Severe Psoriasis, Third Edition**. Koo JYM, Lee CS, Lebwohl MG, Weinstein GD, Gottlieb A, Eds. Informa Healthcare, New York. 2009, 347-364.
107. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, [Blauvelt A](#). Circulating Th17, Th22, and Th1 cells are increased in psoriasis. **J Invest Dermatol** 2010;130:1373-1383.
108. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, [Blauvelt A](#), Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS. IL-17 is essential for host defense against cutaneous *Staphylococcus aureus* infection in mice. **J Clin Invest** 2010;120:1762-1773.
109. Lillis JV, Guo CS, Lee JJ, [Blauvelt A](#). Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis. **Arch Dermatol** 2010;146:918-919.
110. Kagami S, Rizzo HL, Kurtz SE, Miller LS, [Blauvelt A](#). IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against *Candida albicans*. **J Immunol** 2010;185:5453-5462.
111. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, [Blauvelt A](#). Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. **J Am Acad Dermatol** 2010;63:1058-1069.
112. Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, [Blauvelt A](#). IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. **J Immunol** 2011;186:1495-1502.
113. Sugaya M, Reed S, Rose PP, de la Motte S, Raggio CM, Kurtz SE, Moses AV, Früh K, [Blauvelt A](#). Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus express CCL21. **J Dermatol Sci** 2011;61:139-142.
114. Miyagaki T, Sugaya M, Okochi H, Asano Y, Tada Y, Kadono T, [Blauvelt A](#), Tamaki K, Sato S. Blocking MAPK signaling downregulates CCL21 in lymphatic endothelial cells and impairs contact hypersensitivity responses. **J Invest Dermatol** 2011;131:1927-1935.

115. Lee JJ, Mann JA, [Blauvelt A](#). Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab. **J Am Acad Dermatol** 2011;64:999-1000.
116. Pugliese DJ, Gottlieb AB, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, [Blauvelt A](#), Van Voorhees AS. Treatment of psoriasis in the setting of excessive alcohol intake: from the Medical Board of the National Psoriasis Foundation. **Psoriasis Forum** 2011;17:119-130.
117. Sugaya M, Kuwano Y, Suga H, Miyagaki T, Ohmatsu H, Kadono T, Okochi H, [Blauvelt A](#), Tamaki K, Sato S. Lymphatic dysfunction impairs antigen-specific immunization, but augments tissue swelling following contact with allergens. **J Invest Dermatol** 2012;132:667-676.
118. Gottlieb AB, Kalb RE, [Blauvelt A](#), Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. **J Am Acad Dermatol** 2012;67:642-650.
119. Bird JE, Leitenberger JJ, Solomon A, [Blauvelt A](#), Hopkins S. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules. **Dermatol Online J** 2012;18:5.
120. Hsu S, Papp KA, Lebwohl MG, Bagel J, [Blauvelt A](#), Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr. Consensus guidelines for the management of plaque psoriasis. **Arch Dermatol** 2012;148:95-102.
121. Ehst BD, [Blauvelt A](#). Skin Disease in Acute and Chronic Immunosuppression. In: **Fitzpatrick's Dermatology in General Medicine, Eighth Edition**. Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Wolff K, Eds. The McGraw-Hill Companies, Inc., New York. 2012, 330-344.
122. [Blauvelt A](#). Pityriasis Rosea. In: **Fitzpatrick's Dermatology in General Medicine, Eighth Edition**. Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Wolff K, Eds. The McGraw-Hill Companies, Inc., New York. 2012, 458-463.
123. Ehst BD, [Blauvelt A](#). Pathophysiology of psoriasis. **UpToDate** 2012, online.
124. Ogawa Y, Kawamura T, Matsuzawa T, Aoki R, Gee P, Yamashita A, Moriishi K, Yamasaki K, Koyanagi Y, [Blauvelt A](#), Shimada S. Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. **Cell Host Microbe** 2013;13:77-86.
125. Kimura T, Sugaya M, [Blauvelt A](#), Okochi H, Sato S. Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction. **J Leuk Biol** 2013;94:137-145.
126. Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, [Blauvelt A](#), Shimada S. Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV *ex vivo* infection of Langerhans cells within the epithelium. **J Invest Dermatol** 2013;133:2803-2805.
127. Ku JH, Winthrop KL, Varley CD, Sullivan A, Ehst BD, [Blauvelt A](#), Deodhar AA.

- Implications for biologic therapy: Staphylococcus aureus decolonization of individuals with a history of recurrent skin and soft-tissue infections. **JAMA Dermatol** 2013;149:986-989.
128. Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. **J Drugs Dermatol** 2013;12:874-880.
 129. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate** 2013, online.
 130. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on psoriasis and cutaneous oncology: proceedings from the 2013 MauiDerm meeting. **J Clin Aesthet Dermatol** 2013;6:S2-S20.
 131. Varley CD, Deodhar AA, Ehst BD, Bakke A, Blauvelt A, Vega R, Yamashita S, Winthrop KL. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF- α inhibitor therapy. **Rheumatology (Oxford)** 2014;53:332-337.
 132. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tying S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. **N Engl J Med** 2014;371:326-338.
 133. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. **J Am Acad Dermatol** 2014;71:1176-1182.
 134. Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. **J Am Acad Dermatol** 2014;70:168-177.
 135. Blauvelt A. Ustekinumab. In: **Moderate to Severe Psoriasis, Fourth Edition**. Levin E, Leon A, Wu JJ, Gottlieb AB, Koo JYM, Eds. CRC Press, Boca Raton. 2014, 217-230.
 136. Bhatia N, Blauvelt A, Brown M, High W, Leonardi CT, Rosen T, Stein Gold L, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on psoriasis and cutaneous oncology: proceedings from the 2014 MauiDerm Meeting. **J Clin Aesthet Dermatol** 2014;7:S5-S22.
 137. Kimura T, Sugaya M, Oka T, Blauvelt A, Okochi H, Sato S. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. **Oncotarget** 2015;6:18081-18093.
 138. Garg N, Truong B, Ku JH, Devere TS, Ehst BD, Blauvelt A, Deodhar AA. A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. **Clin Rheumatol** 2015;34:1745-1751.

139. [Blauvelt A](#), Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). **Br J Dermatol** 2015;172:484-493.
140. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; [UNCOVER-2 and UNCOVER-3 investigators](#). Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. **Lancet** 2015;386:541-551.
141. Thaçi D, [Blauvelt A](#), Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. **J Am Acad Dermatol** 2015;73:400-409.
142. Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, [Blauvelt A](#), Martin R, Papavassilis C, Mpfu S. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. **J Drugs Dermatol** 2015;14:821-833.
143. Truong B, Rich-Garg N, Ehst BD, Deodhar AA, Ku JH, Vakil-Gilani K, Danve A, [Blauvelt A](#). Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. **Clin Cosmet Investig Dermatol** 2015;8:563-569.
144. [Blauvelt A](#), Lebwohl M, Bissonnette R. Interleukin-23/interleukin-17A dysfunction phenotypes inform possible clinical effects from anti-interleukin-17A therapies. **J Invest Dermatol** 2015;135:1946-1953.
145. Ehst BD, [Blauvelt A](#). Pathophysiology of psoriasis. **UpToDate** 2015, online.
146. [Blauvelt A](#), Armstrong AW, Krueger GG. Essential truths for the care and management of moderate-to-severe psoriasis. **J Drugs Dermatol** 2015;14:805-812.
147. Muram TM, Sloan JH, Chain JS, Komocsar WJ, Meiklejohn BI, [Blauvelt A](#), Papp KA, Heffernan MP, Qian YW, Konrad RJ. A highly sensitive and drug-tolerant anti-drug antibody screening assay for ixekizumab using affinity capture elution. **J Invest Dermatol** 2016;136:1513-1515.
148. Thaçi D, Simpson EL, Beck LA, Bieber T, [Blauvelt A](#), Papp K, Soong W, Worm M, Szepletowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. **Lancet** 2016;387:40-52.
149. Papp KA, Reich K, Paul C, [Blauvelt A](#), Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. **Br J Dermatol** 2016;175:273-286.

150. Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. **J Am Acad Dermatol** 2016;75:77-82.
151. van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. **J Am Acad Dermatol** 2016;75:83-98.
152. Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Sutherland ER, Mastey V. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). **J Am Acad Dermatol** 2016;75:506-515.
153. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. **N Engl J Med** 2016;375:345-356.
154. Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. **J Drugs Dermatol** 2016;15:1226-1234.
155. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. **N Engl J Med** 2016;375:2335-2348.
156. Blauvelt A, Cohen AD, Puig L, Vender R, van der Walt J, Wu JJ. Biosimilars for psoriasis: pre-clinical analytical assessment to determine similarity. **Br J Dermatol** 2016;174:282-286.
157. Blauvelt A. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to-severe plaque psoriasis. **Expert Opin Biol Ther** 2016;16:255-263.
158. Blauvelt A. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. **PracticeUpdate** <http://www.practiceupdate.com/content/tnf-inhibitors-improve-insulin-sensitivity-in-psoriasis-patients-with-type-2-diabetes/37580/65/4/1>. April 27, 2016.
159. Blauvelt A. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. **PracticeUpdate** <http://www.practiceupdate.com/content/ixekizumab-in-moderate-to-severe-plaque-psoriasis/40425/65/4/1>. July 12, 2016.

160. Armstrong AW, Bukhalo M, Blauvelt A. A clinician's guide to the diagnosis and treatment of candidiasis in patients with psoriasis. **Am J Clin Dermatol** 2016;17:329-336.
161. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. **Expert Opin Drug Saf** 2016;15:1413-1420.
162. Kagha KC, Blauvelt A, Anderson KL, Leonardi CL, Feldman SR. A boxed warning for inadequate psoriasis treatment. **Cutis** 2016;98:206-207.
163. Blauvelt A. Head-to-head comparison of secukinumab versus ustekinumab for psoriasis. **PracticeUpdate** <http://www.practiceupdate.com/content/secukinumab-issuperior-to-ustekinumab-in-clearing-moderate-to-severe-plaque-psoriasis-up-to-1year/44533/65/4/1>. October 18, 2016.
164. Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E. Updates on psoriasis and cutaneous oncology: proceedings from the 2016 MauiDerm Meeting. **J Clin Aesthet Dermatol** 2016;9:S5-S29.
165. Reich K, Blauvelt A, Armstrong A, Langley RG, Fox T, Huang J, Papavassilis C, Liang E, Lloyd P, Bruin G. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. **Br J Dermatol** 2017;176:752-758.
166. Blauvelt A, Reich K, Tsai TF, Tying S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. **J Am Acad Dermatol** 2017;76:60-69.
167. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. **J Am Acad Dermatol** 2017;76:405-417.
168. Blauvelt A, Papp KA, Griffiths CE, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and safety of switching to ixekizumab in etanercept nonresponders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3). **Am J Clin Dermatol** 2017;18:273-280.
169. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger J, Lacour JP, Menter A, Philipp S, Sofen H, Tying S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. **N Engl J Med** 2017;376:1551-1560.
170. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemeny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY

AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. **Lancet** 2017;389:2287-2303.

171. [Blauvelt A](#), Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. **J Eur Acad Dermatol Venereol** 2017;31:1004-1013.
172. [Blauvelt A](#), Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). **J Am Acad Dermatol** 2017;77:372-374.
173. Reich K, Papp KA, [Blauvelt A](#), Tying SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. **Lancet** 2017;390:276-288.
174. [Blauvelt A](#), Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikai E, Dey D, Mallbris L, Reich K. Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. **Br J Dermatol** 2017;177:587-590.
175. Leonardi CL, [Blauvelt A](#), Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K. Rapid Improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. **J Eur Acad Dermatol Venereol** 2017;31:1483-1490.
176. [Blauvelt A](#), Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tying SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB. Secukinumab reinitiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. **Br J Dermatol** 2017;177:879-881.
177. [Blauvelt A](#), Gooderham M, Iversen L, Ball S, Zhang L, Agada NO, Reich K. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). **J Am Acad Dermatol** 2017;77:855-862.
178. [Blauvelt A](#), Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tying S. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. **J Eur Acad Dermatol Venereol** 2017;31:1693-1699.
179. Papp KA, Bachelez H, [Blauvelt A](#), Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. **Br J Dermatol** 2017;177:1537-1551.

180. [Blauvelt A](#), Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Munoz-Elias EJ, Callis Duffin K. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). **Br J Dermatol** 2017;177:1552-1561.
181. [Blauvelt A](#), Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, Skov L, Zachariae C, Young H, Prens E, Cohen A, van der Walt J, Wu JJ. Biosimilars for psoriasis: clinical studies to determine similarity. **Br J Dermatol** 2017;177:23-33.
182. [Blauvelt A](#). IL-6 differs from TNF- α : unpredicted clinical effects caused by IL-6 blockade in psoriasis. **J Invest Dermatol** 2017;137:541-542.
183. Ehst BD, [Blauvelt A](#). Pathophysiology of psoriasis. **UpToDate** 2017, online.
184. Cohen AD, Wu JJ, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, de la Cruz C, Skov L, Zachariae C, Young HS, Foley P, van der Walt JM, Naldi L, Prens EP, [Blauvelt A](#). Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. **Br J Dermatol** 2017;177:1495-1502.
185. Loesche MA, Farahi K, Capone K, Fakharzadeh S, [Blauvelt A](#), Callis Duffin K, DePrimo SE, Munoz-Elias EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA. Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. **J Invest Dermatol** 2018;138:1973-1981.
186. Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, Muram TM, [Blauvelt A](#). Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis. **J Invest Dermatol** 2018;138:2168-2173.68.
187. Lebwohl MG, Papp KA, Marangell LB, Koo J, [Blauvelt A](#), Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. **J Am Acad Dermatol** 2018;78:81-89.
188. Shear NH, Paul C, [Blauvelt A](#), Gooderham M, Leonardi C, Reich K, Ohtsuki M, Pangallo B, Xu W, Ball S, Ridenour T, Torisu-Itakura H, Agada N, Mallbris L. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. **J Drugs Dermatol** 2018;17:200-206.
189. Gordon KB, [Blauvelt A](#), Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. **Br J Dermatol** 2018;178:132-139.
190. Puig L, Augustin M, [Blauvelt A](#), Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG. Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study. **J Am Acad Dermatol** 2018;78:741-748.

191. Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). **Br J Dermatol** 2018;178:674-681.
192. Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. **J Dermatolog Treat** 2018;29:220-229.
193. Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P. Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). **Br J Dermatol** 2018;178:1315-1323.
194. Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. **JAMA Dermatol** 2018;154:676-683.
195. Lebwohl M, Blauvelt A, Paul C, Sofen H, Weglowska J, Piguat V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). **J Am Acad Dermatol** 2018;79:266-276.
196. Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. **J Am Acad Dermatol** 2018;79:277-286.
197. Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. **J Am Acad Dermatol** 2018;79:294-301.
198. Gottlieb AB, Blauvelt A, Taçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). **J Am Acad Dermatol** 2018;79:302-314.
199. Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years. **J Drugs Dermatol** 2018;17:826-832.
200. Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. **J Eur Acad Dermatol Venereol** 2018;32:1515-1522.

201. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. **Lancet** 2018;392:650-661.
202. Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials. **J Am Assoc Nurse Pract** 2018;30:529-541.
203. Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tying SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. **Br J Dermatol** 2018;179:615-622.
204. Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, Jauch-Lembach J, Balfour A, Leonardi CL. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. **Br J Dermatol** 2018;179:623-631.
205. Baumann LS, Blauvelt A, Draelos ZD, Kempers SE, Lupo MP, Schlessinger J, Smith SR, Wilson DC, Bradshaw M, Estes E, Shanler SD. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). **J Am Acad Dermatol** 2018;79:869-877.
206. Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. **Br J Dermatol** 2018;179:844-852.
207. Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). **Dermatol Ther (Heidelb)** 2018;8:571-579.
208. Siegfried EC, Jaworski JC, Eichenfield LF, Paller A, Hebert AA, Simpson EL, Altman E, Arena C, Blauvelt A, Block J, Boguniewicz M, Chen S, Cordoro K, Hanna D, Horii K, Hultsch T, Lee J, Leung DY, Lio P, Milner J, Omachi T, Schneider C, Schneider L, Sidbury R, Smith T, Sugarman J, Taha S, Tofte S, Tollefson M, Tom WL, West DP, Whitney L, Zane L. Developing drugs for treatment of atopic dermatitis in children (≥ 3 months to < 18 years of age): draft guidance for industry. **Pediatr Dermatol** 2018;35:303-322.
209. Blauvelt A. Dual inhibition of IL-12/IL-23 and selective inhibition of IL-23 in psoriasis. In: **Biologic and Systemic Agents in Dermatology**. Yamauchi PS, Ed. Springer, Cham, Switzerland. 2018, 123-131.

210. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. **Drugs** 2018;78:463-478.
211. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Authors' reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes." **Drugs** 2018;78:853-855.
212. Blauvelt A. Vaccination in the setting of dupilumab therapy for atopic dermatitis. **PracticeUpdate** <http://www.practiceupdate.com/content/dupilumab-does-not-affectcorrelates-of-vaccine-induced-immunity/72266/65/4/1>. August 30, 2018.
213. Strober BE, Gelfand JM, Blauvelt A, Kavanaugh A, Leonardi CL, Stein Gold L. Updates in psoriasis management: proceedings from the 2018 MauiDerm meeting. **J Clin Aesthet Dermatol** 2018;11:S6-S23.
214. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. **Clin Rev Allergy Immunol** 2018;55:379-390.
215. Blauvelt A, Shumel B. Response to critical appraisal of LIBERTY AD CHRONOS. **Br J Dermatol** 2018;179:1423.
216. Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. **J Eur Acad Dermatol Venereol** 2019;33:1733-1741.
217. Blauvelt A, Simpson EL, Tying SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. **J Am Acad Dermatol** 2019;80:158-167.
218. Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tying S, Rastogi S, Pillai R, Israel R. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. **Br J Dermatol** 2019;180:306-314.
219. Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Roller R, Gottlieb AB. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. **J Eur Acad Dermatol Venereol** 2019;33:546-552.
220. Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R. Efficacy of a once-daily fixed combination halobetasol (0.01%) and tazarotene (0.045%) lotion in the treatment of localized moderate-to-severe plaque psoriasis. **J Drugs Dermatol** 2019;18:297-299.
221. Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. **Arthritis Res Ther** 2019;21:111-121.
222. Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP. Long-term safety of

certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. **RMD Open** 2019;5:e942-e955.

223. Papp KA, Reich K, [Blauvelt A](#), Kimball AB, Gooderham M, Tying SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. **J Eur Acad Dermatol Venereol** 2019;33:1098-1106.
224. [Blauvelt A](#), Rosmarin D, Bieber T, Simpson EL, Bagel J, Worm M, Deleuran M, Katoñ N, Kawashima M, Shumel B, Chen Z, Rossi AB, Hultsch T, Ardeleanu M. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase 3 clinical trials. **Br J Dermatol** 2019;181:196-197.
225. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, [Blauvelt A](#), Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Conjunctivitis in dupilumab clinical trials. **Br J Dermatol** 2019;181:459-473.
226. Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, [Blauvelt A](#). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. **Lancet** 2019;394:831-839.
227. Thaçi D, Puig L, Reich K, Tsai TF, Tying S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, [Blauvelt A](#). Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. **J Am Acad Dermatol** 2019;81:1405-1409.
228. Papp K, [Blauvelt A](#), Sullivan J, Tada Y, Polzer P, Mallbris L, Zhang L, Hong C. Ixekizumab - an effective and safe treatment for moderate-to-severe plaque psoriasis in patients previously treated with other IL-17 inhibitors: results from IXORA-P. **J Psoriasis Psoriatic Arthritis** 2019;4:180-185.
229. [Blauvelt A](#), Sofen H, Papp K, Gooderham M, Tying S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. **J Eur Acad Dermatol Venereol** 2019;33:2305-2312.
230. Lebwohl MG, [Blauvelt A](#), Menter A, Papp KA, Guenther S, Pillai R, Israel RJ, Jacobson A. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis patients treated with brodalumab for 5 years in a long-term, open-label, phase II study. **Am J Clin Dermatol** 2019;20:863-871.
231. [Blauvelt A](#), Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ. Comparison of health care costs among patients

- with psoriasis initiating ixekizumab, secukinumab, or adalimumab. **J Manag Care Spec Pharm** 2019;25:1366-1376.
232. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate** 2019, online.
233. Blauvelt A. Predicting clinical responses to ustekinumab: progress toward a future of personalized medicine. **JAMA Dermatol** 2019;155:1227-1228.
234. Kimball AB, Kerbusch T, van Aarle F, Kulkarni P, Li Q, Blauvelt A, Papp KA, Reich K, Montgomery D. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. **Br J Dermatol** 2020;182:180-189.
235. Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. **J Am Acad Dermatol** 2020;82:117-122.
236. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. **JAMA Dermatol** 2020;156:44-56.
237. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Dupilumab shows long-term safety and efficacy with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. **J Am Acad Dermatol** 2020;82:377-388.
238. Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. **J Dermatolog Treat** 2020;31:141-146.
239. Armstrong A, Paul C, Puig L, Boehncke WH, Freeman M, Torii H, Papp K, Griffiths CEM, Blauvelt A, Reich K, Gooderham M, Terui T, Renda L, Agada N, Xu W, Gallo G, Lebwohl MG. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. **Dermatol Ther (Heidelb)** 2020;10:133-150.
240. Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, Guttman-Yassky E, Hultsch T, Chen Z, Mina-Osorio P, Lu Y, Rossi AB, He X, Kamal M, Graham NMH, Pirozzi G, Ruddy M, Eckert L, Gadkari A. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: posthoc analyses from a randomized clinical trial. **Am J Clin Dermatol** 2020;21:119-131.
241. Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis:

- pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. **Br J Dermatol** 2020;182:605-617.
242. [Blauvelt A](#), Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ. Comparison of real-world treatment patterns among psoriasis patients treated with ixekizumab or adalimumab. **Patient Preference Adherence** 2020;14:517-527.
 243. [Blauvelt A](#), Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. **J Am Acad Dermatol** 2020;82:927-935.
 244. Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, [Blauvelt A](#). Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. **J Am Acad Dermatol** 2020;82:936-945.
 245. Hsu S, Green LJ, Lebwohl MG, Wu JJ, [Blauvelt A](#), Jacobson AA. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. **Br J Dermatol** 2020;182:880-888.
 246. Guttman-Yassky E, [Blauvelt A](#), Eichenfield LF, Paller AS, Armstrong AW, Drew J, Gopalan R, Simpson EL. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. **JAMA Dermatol** 2020;156:411-420.
 247. Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, [Blauvelt A](#). Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. **J Am Acad Dermatol** 2020;82:1138-1149.
 248. Wollenberg A, Beck LA, [Blauvelt A](#), Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). **Br J Dermatol** 2020;182:1120-1135.
 249. [Blauvelt A](#), Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. **Br J Dermatol** 2020;182:1348-1358.
 250. Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, [Blauvelt A](#). Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. **Br J Dermatol** 2020;182:1359-1368.
 251. Armstrong AW, [Blauvelt A](#), Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A. Defining drug-free remission of

- skin disease in patients with plaque psoriasis. **Br J Dermatol** 2020;182:1484-1487.
252. Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. **JAMA Dermatol** 2020;156:649-658.
253. Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M, Hide M, Sher L, Hussain I, Chen Z, Khokhar FA, Beazley B, Ruddy M, Patel N, Graham NMH, Ardeleanu M, Shumel B. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in open-label study of adults with moderate-to-severe atopic dermatitis. **Am J Clin Dermatol** 2020;21:567-577.
254. Gelfand JM, Shin DB, Callis Duffin K, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Prasad Sarkar R, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Werner TJ, Alavi A, Mehta NN. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). **J Invest Dermatol** 2020;140:1784-1793.
255. Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, Wang M, Cioffi C, Griffiths CEM. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. **J Am Acad Dermatol** 2020;83:1367-1374.
256. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 1. **J Am Acad Dermatol** 2020;83:1704-1716.
257. Weyne J, Blauvelt A, de Bruin-Weller M, Prens E, Asbell P, Sierka D, Chen Z, Shumel B. Patient-reported ocular disorders and symptoms in adults with moderate-to-severe atopic dermatitis: screening and baseline survey data from a clinical trial. **Dermatol Ther (Heidelb)** 2020;10:1415-1421.
258. Blauvelt A, Chiricozzi A, Ehst BD. Bimekizumab. **Curr Derm Rep** 2020;9:36-42.
259. Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. **J Drugs Dermatol** 2020;19:487-492.
260. Blauvelt A, Ehst BD. Reply to: Do IL-17 inhibitors increase risk of respiratory tract infections? **J Am Acad Dermatol** 2020;83:e303-e304.
261. LeQuang JA, Blauvelt A, Gelfand JM, Stein Gold S, Kavanaugh A, Leonardi CL. Updates in psoriasis management 2020-based on selected presentations from MauiDerm 2020, January 25-29, 2020, Maui, Hawaii. **J Clin Aesthet Dermatol** 2020;13:S7-S23.

262. [Blauvelt A](#). COVID-19 and psoriasis: new guidance from the NPF. **J Psoriasis Psoriatic Arthritis** 2020;5:129-130.
263. Krueger JG, Murrell DF, Garcet S, Navrazhina K, Lee PC, Muscianisi E, [Blauvelt A](#). Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. **J Allergy Clin Immunol** 2021;147:1107-1109.
264. [Blauvelt A](#), Burge R, Malatestinic W, Brnabic A, Guo J, Janardhanan M, Zhu B. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. **J Manag Care Spec Pharm** 2021;27:84-94.
265. Warren RB, [Blauvelt A](#), Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. **Br J Dermatol** 2021;184:50-59.
266. Bagel J, [Blauvelt A](#), Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). **J Eur Acad Dermatol Venereol** 2021;35:135-142.
267. Bansal A, Simpson EL, Paller AS, Siegfried EC, [Blauvelt A](#), de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma. **Am J Clin Dermatol** 2021;22:101-115.
268. Golbari NM, van der Walt JM, [Blauvelt A](#), Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. **J Eur Acad Dermatol Venereol** 2021;35:417-421.
269. Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, [Blauvelt A](#). Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. **Lancet** 2021;397:475-486.
270. Reich K, Papp KA, [Blauvelt A](#), Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial. **Lancet** 2021;397:487-498.
271. [Blauvelt A](#), Kempers S, Lain E, Schlesinger T, Tying S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MFR. Phase 3 trials of tirbanibulin ointment for actinic keratosis. **N Engl J Med** 2021;384:512-520.
272. Wollenberg A, [Blauvelt A](#), Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL. Tralokinumab for moderate-to-severe atopic dermatitis: results from

- two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). **Br J Dermatol** 2021;184:437-449.
273. Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaci D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. **J Allergy Clin Immunol Pract** 2021;9:1212-1223.
274. Blauvelt A, Leonardi CL, Gaylis N, Jauch-Lembach J, Balfour A, Lemke L, Hachaichi S, Brueckmann I, Festini T, Wiland P. Treatment with SDZ-ADL, an adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase III studies (ADMYRA and ADACCESS). **BioDrugs** 2021;35:229-238.
275. Blauvelt A. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). **PracticeUpdate** <https://www.practiceupdate.com/content/tralokinumab-for-moderate-to-severe-atopic-dermatitis/111886/65/4/1>. January 18, 2021.
276. Blauvelt A, Strober B. How to best define psoriasis severity: a new consensus statement from the International Psoriasis Council. **J Psoriasis Psoriatic Arthritis** 2021;6:6-7.
277. Blauvelt A, Paul C, van de Kerkhof P, Warren RB, Gottlieb AB, Langley RG, Brock F, Arendt C, Boehnlein M, Lebwohl M, Reich K. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. **Br J Dermatol** 2021;184:640-651.
278. Gordon KB, Warren RB, Gottlieb AB, Blauvelt A, Thaci D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, Reich K. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). **Br J Dermatol** 2021;184:652-662.
279. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: version 2 – advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. **J Am Acad Dermatol** 2021;84:1254-1268.
280. Gondo GC, Bell SJ, Slayden J, Ullman G, Blauvelt A. Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. **J Eur Acad Dermatol Venereol** 2021;35:e354-e355.
281. Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque

- psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. **Br J Dermatol** 2021;184:1047-1058.
282. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HCH, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. **Lancet** 2021;397:2151-2168.
283. Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YCM, Maari C, Reich K, Blauvelt A, Bissonnette R, Muñoz-Elías EJ, Sarfati M. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. **J Invest Dermatol** 2021;141:1707-1718.
284. Abuabara K, Nicholls SG, Langan SM, Guttman-Yassky E, Reynolds NJ, Paller AS, Brown SJ; International Eczema Council Priority Research Group. Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. **Br J Dermatol** 2021;185:203-205.
285. Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K. Bimekizumab versus adalimumab in plaque psoriasis. **N Engl J Med** 2021;385:130-141.
286. Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A. Bimekizumab versus secukinumab in plaque psoriasis. **N Engl J Med** 2021;385:142-152.
287. Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, Gallo G, Paul C. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. **J Am Acad Dermatol** 2021;85:360-368.
288. Foley P, Reich K, Blauvelt A, Bagel J, Langley RG, Miller M, Ramachandran P, Wen Yang Y, Shen YK, You Y, Lebwohl M, Griffiths CEM. Serious gastrointestinal-related adverse events among psoriasis patients treated with guselkumab in VOYAGE 1 and VOYAGE 2 through 4 years of treatment. **J Drugs Dermatol** 2021;20:855-860.
289. Bykerk VP, Blauvelt A, Curtis JR, Gaujoux-Viala C, Kvien TK, Winthrop K, Tilt N, Popova C, Mariette X, Haraoui B. Associations between safety of certolizumab pegol, disease activity, and patient characteristics, including corticosteroid use and body mass index. **ACR Open Rheumatol** 2021;3:501-511.
290. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, de Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. **JAMA Dermatol** 2021;157:1047-1055.
291. Ehst BD, Blauvelt A. Pathophysiology of psoriasis. **UpToDate** 2021, online.
292. Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, Myers B, Shi ZR, Yosipovitch G, Bell S, Liao W. New frontiers in psoriatic disease research, part II: comorbidities and targeted therapies. **J Invest Dermatol** 2021;141:2328-2337.

293. [Blauvelt A](#), Ramharter M, Cohen AD, Xu W, Patel H, Schuster C, Riedl E, Puig L. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. **J Eur Acad Dermatol Venereol** 2021;35:e828-e831.
294. Freitas E, [Blauvelt A](#), Torres T. Bimekizumab for the treatment of psoriasis. **Drugs** 2021;81:1751-1762.
295. Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, Arendt C, Fierens F, [Blauvelt A](#). Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. **J Eur Acad Dermatol Venereol** 2021;35:2398-2408.
296. [Blauvelt A](#), Shi N, Burge R, Somani N, Ridenour TL, Zhu B, Atiya B, Lew CR, Zimmerman NM, Murage MJ. Comparison of real-world treatment patterns among biologic-experienced patients with psoriasis treated with ixekizumab or secukinumab over 18 months. **Dermatol Ther (Heidelb)** 2021;2133-2145.
297. Gondo GC, Merola JF, Bell SJ, [Blauvelt A](#). Decreased quality of life in people with psoriasis and psoriatic arthritis versus people with psoriasis alone: data from a national US survey. **Br J Dermatol** 2021;185:1264-1265.
298. [Blauvelt A](#), Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Ricardo Criado P, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. **J Am Acad Dermatol** 2022;86:104-112.
299. Krueger JG, McInnes IB, [Blauvelt A](#). Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. **J Am Acad Dermatol** 2022;86:148-157.
300. [Blauvelt A](#), de Bruin-Weller M, Simpson EL, Chen Z, Ardeleanu M, Rossi AB. Consistency of response to dupilumab in adults with moderate-to-severe atopic dermatitis over 1 year. **Dermatol Ther (Heidelb)** 2022;12:9-13.
301. Armstrong A, [Blauvelt A](#), Simpson EL, Smith CH, Herranz P, Kataoka Y, Seo SJ, Ferrucci SM, Chao J, Chen Z, Rossi AB, Shumel B, Tomondy P. Continued treatment with dupilumab is associated with improved efficacy in adults with moderate-to-severe atopic dermatitis not achieving optimal responses with short-term treatment. **Dermatol Ther (Heidelb)** 2022;12:195-202.
302. [Blauvelt A](#), de Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B. Dupilumab with topical corticosteroids provides rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across anatomic regions over 52 weeks. **Dermatol Ther (Heidelb)** 2022;12:223-231.
303. [Blauvelt A](#), Shi N, Somani N, Burge R, Zhu B, Ridenour TL, Lew CR, Zimmerman NM, Atiya B, Murage MJ. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. **J Am Acad Dermatol** 2022;86:581-589.

304. Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhall R, Reich K. Long-term safety of risankizumab treatment from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. **Br J Dermatol** 2022;186:466-475.
305. Blauvelt A, Burge R, Gallo G, Charbonneau B, Malatestinic W, Zhu B, Wan F, Lockshin B. A retrospective cohort analysis of treatment patterns over 1 year in patients with psoriasis treated with ixekizumab or guselkumab. **Dermatol Ther (Heidelb)** 2022;12:701-714.
306. Blauvelt A, Gooderham M, Griffiths CEM, Armstrong AW, Zhu B, Burge R, Gallo G, Guo J, Garrelts A, Lebwohl M. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis. **Dermatol Ther (Heidelb)** 2022;12:727-740.
307. Armstrong AW, Blauvelt A, Mrowietz U, Strober B, Gisondi P, Merola JF, Langley RG, Ståhle M, Lebwohl M, Netea MG, Nunez Gomez N, Warren RB. A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17. **Dermatol Ther (Heidelb)** 2022;12:787-800.
308. Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, Yang YW, Papp KA, Puig L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. **J Am Acad Dermatol** 2022;86:827-834.
309. Griffiths CEM, Papp KA, Song M, Miller M, You Y, Shen YK, Han C, Blauvelt A. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. **J Dermatolog Treat** 2022;33:848-856.
310. Blauvelt A, Shi N, Murage M, Ridenour T, Lew C, Somani N, Zhu B, Zimmerman N, Kern S, Burge R. Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: a real-world study. **J Drugs Dermatol** 2022;21:399-407.
311. Paller AS, Beck LA, Blauvelt A, Siegfried EC, Cork MJ, Wollenberg A, Chen Z, Khokhar FA, Vakil J, Zhang A, Bansal A, Cyr SL. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—a pooled analysis of trial data. **Pediatr Dermatol** 2022;39:187-196.
312. Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HCH, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. **JAMA Dermatol** 2022;158:404-413.
313. King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R, BRAVE-AA investigators. Two phase 3 trials of baricitinib for alopecia areata. **N Engl J Med** 2022;386:1687-1699.

314. Elewski BE, [Blauvelt A](#), Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis. **Dermatol Ther (Heidelb)**. 2022;12:911-920.
315. Boki H, Kimura T, Miyagaki T, Suga H, [Blauvelt A](#), Okochi H, Sugaya M, Sato S. Lymphatic dysfunction exacerbates cutaneous tumorigenesis and psoriasis-like skin inflammation through accumulation of inflammatory cytokines. **J Invest Dermatol** 2022;142:1692-1702.
316. [Blauvelt A](#), Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). **Am J Clin Dermatol** 2022;23:365-383.
317. [Blauvelt A](#), Shi N, Murage MJ, Kern SA, Somani N, Burge R, Ridenour TL, Lew CR, Zimmerman NM, Zhu B. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over two years of follow-up in real-world settings. **J Med Econ** 2022;25:741-749.
318. Yilmaz K, Goletz S, Pas HH, van den Bos RR, [Blauvelt A](#), White WL, Bouaziz JD, Zuelgaray E, Daneshpazhooh M, Yancey KB, Goebeler M, Schmidt E. Clinical and serological characterization of orf-induced immunobullous disease. **JAMA Dermatol** 2022;158:670-674.
319. Griffiths CEM, Gooderham M, Colombel JF, Terui T, Accioly AP, Gallo G, Zhu D, [Blauvelt A](#). Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. **Dermatol Ther (Heidelb)** 2022;12:1431-1446.
320. Leonardi CL, Zhu B, Malatestinic WN, Eastman WJ, Guo J, Murage MJ, Kar-Chan Choong C, Burge R, [Blauvelt A](#). Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan® databases. **Adv Ther** 2022;39:3214-3224.
321. [Blauvelt A](#), Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. **J Dermatolog Treat** 2022;33:2085-2093.
322. [Blauvelt A](#), Armstrong AW, Langley RG, Gebauer K, Thaçi D, Bagel J, Guenther LC, Paul C, Randazzo B, Flavin S, Hsu MC, You Y, Reich K. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. **J Dermatolog Treat** 2022;33:2317-2324.
323. Reich K, Thyssen JP, [Blauvelt A](#), Eyerich K, Soong W, Rice ZP, Hong CH, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Efficacy and safety of abrocitinib versus dupilumab in adults with

moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. **Lancet** 2022;400:273-282.

324. [Blauvelt A](#), Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. **J Dermatolog Treat** 2022;33:2605-2613.
325. Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, [Blauvelt A](#). Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. **BioDrugs** 2022;36:625-637.
326. [Blauvelt A](#), Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, Wollenberg A, Herranz P, Pink AE, Peris K, Fangel S, Gjerum L, Corriveau J, Saeki H, Warren RB, Simpson E, Reich K. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. **J Am Acad Dermatol** 2022;87:815-824.
327. [Blauvelt A](#). Resident memory T cells in psoriasis: key to a cure? **J Psoriasis Psoriatic Arthritis** 2022;7:157-159.
328. Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; [TRuE-V Study Group](#). **N Engl J Med** 2022;387:1445-1455.
329. Reich K, Gordon KB, Strober B, Langley RG, Miller M, Yang YW, Shen YK, You Y, Zhu Y, Foley P, [Blauvelt A](#). Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. **J Eur Acad Dermatol Venereol** 2022;36:2393-2400.
330. [Blauvelt A](#), Pink A, Worm M, Langley RGB, Elewski BE, Gjerum L, Guttman-Yassky E. Outcomes of COVID-19 and vaccination in patients with moderate to severe atopic dermatitis treated with tralokinumab. **JAMA Dermatol** 2022;158:1327-1330.
331. [Blauvelt A](#), Gooderham M, Bhatia N, Langley RG, Schneider S, Zoidis J, Kurbasic A, Armstrong A, Silverberg JI. Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: a subanalysis of phase 3 trials ECZTRA 1, 2, and 3. **Dermatol Ther (Heidelb)** 2022;12:2499-2516.
332. [Blauvelt A](#), Shi N, Burge R, Atiya B, Zhu B, Somani N, Ridenour T, Lew CR, Zimmerman NM, Murage MJ. Healthcare costs among patients with psoriasis treated with ixekizumab versus secukinumab in real-world settings over 24 months. **Pharmacoecoon Open** 2022;6:871-880.
333. [Blauvelt A](#), Kimball AB, Augustin M, Okubo Y, Witte MM, Rodriguez Capriles C, Sontag A, Arora V, Osuntokun O, Strober B. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). **Br J Dermatol** 2022;187:866-877.
334. Gelfand JM, Shin DB, Armstrong AW, Tyring SK, [Blauvelt A](#), Gottlieb S, Lockshin BN, Kalb RE, Fitzsimmons R, Rodante J, Parel P, Manyak GA, Mendelsohn L, Noe MH, Papadopoulos M, Syed MN, Werner TJ, Wan J, Playford MP, Alavi A, Mehta

- NN. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial. **JAMA Dermatol** 2022;158:1394-1403.
335. [Blauvelt A](#), Kircik L, Papp KA, Simpson EL, Silverberg JI, Kim BS, Kwatra SG, Kuligowski ME, Venturanza ME, Wei S, Szepietowski JC. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. **J Eur Acad Dermatol Venereol** 2023;37:137-146.
336. Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, [Blauvelt A](#). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. **J Am Acad Dermatol** 2023;88:29-39.
337. [Blauvelt A](#), Wollenberg A, Eichenfield LF, Zhang H, Sierka D, Khokhar FA, Vakil J, Shabbir A, Rodriguez Marco A, Cyr SL. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. **Adv Ther** 2023;40:367-380.
338. [Blauvelt A](#), Szepietowski JC, Papp K, Simpson EL, Silverberg JI, Kim BS, Kwatra SG, Kuligowski ME, Wei S, Kircik L. Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: pooled analysis from two randomized phase 3 studies. **J Am Acad Dermatol** 2022; Sep 14.
339. [Blauvelt A](#), Pariser DM, Tying S, Bagel J, Alexis AF, Soung J, Armstrong AW, Muscianisi E, Kianifard F, Steadman J, Prasad Sarkar R, Garcet S, Krueger JG. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. **J Dermatol Sci** 2023; Jan 9.
340. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Gontijo Lima R, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, [Blauvelt A](#). Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). **JAMA Dermatol** 2023; Jan 11.
341. Silverberg JI, Guttman-Yassky E, Thaci D, Irvine AD, Stein Gold L, [Blauvelt A](#), Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. **N Engl J Med** 2023; in press.
342. Kokolakis G, Warren RB, Strober B, [Blauvelt A](#), Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: results from phase 3/3b trials. **Br J Dermatol** 2023; in press.
343. [Blauvelt A](#), Shi N, Somani N, Burge R, Zhu B, Ridenour T, Kern S, Lew C, Zimmerman N, Murage M. Comparison of real-world costs, healthcare resource utilization, and comorbidity-related costs between ixekizumab and secukinumab among biologic-experienced patients with psoriasis over 18 months in the United States. **Clin Drug Invest** 2023; in press.

344. Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox MA, Garcia Gil E, Silverberg J. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials. **Br J Dermatol** 2023; in press.
345. Blauvelt A, Gondo GC, Bell S, Echeverría C, Schmitt-Egenolf M, Skov L, van de Kerkhof P, McCormick Howard L, Strober B. Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. **J Psoriasis Psoriatic Arthritis** 2023; in press.
346. Strober B, Paul C, Blauvelt A, Thaçi D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Nunez Gomez N, Eyerich K. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. **J Am Acad Dermatol**. Submitted.
347. Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). **J Am Acad Dermatol**. Submitted.
348. Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaçi D, Foley P, Papp KA. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials. **J Am Acad Dermatol**. Submitted.
349. Blauvelt A, Langley RG, Branigan PJ, Liu X, Chen Y, DePrimo S, Ma K, Scott B, Campbell K, Muñoz-Elías EJ, Papp KA. Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy. **JID Innovations**. Submitted.
350. Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong CH, Imafuku S, Schuttelaar MLA, Simpson EL, Soong W, Arlert P, Wendicke Lophaven K, Kurbasic A, Soldbro L, Strange Vest N, Wollenberg A. Tralokinumab in adolescents with moderate-to-severe atopic dermatitis: a 52-week, randomized, double-blinded, placebo-controlled, phase 3 trial (ECZTRA 6). **JAMA Dermatol**. Submitted.
351. Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW. Residual lesional gene expression in psoriasis patients with complete skin clearance treated with guselkumab or adalimumab in VOYAGE 1 & 2. **J Invest Dermatol**. Submitted.
352. Blauvelt A, Thaçi D, Papp KA, Ho V, Ghoreschi K, Soo Kim B, Miller M, Shen YK, You Y, Chan D, Yu J, Yang YW, Lebwohl M, Gottlieb AB, Crowley J, Foley P. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. **Br J Dermatol**. Submitted.

353. Ehst BD, Strober S, Blauvelt A, Maslin D, Macaro D, Carpenter N, Bodmer M, McHale D. A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of *Prevotella histicola*, in adults with mild-to-moderate plaque psoriasis. **J Am Acad Dermatol**. Submitted.
354. Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis A, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Deucravacitinib in moderate to severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). In preparation. **Br J Dermatol**. Submitted.
355. Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm WK, Pauser S, Correa Da Rosa J, Martel BC, Madsen DE, Røpke M, Arlert P, Steffensen L, Blauvelt A, Reich K. Targeting IL-13 with tralokinumab progressively normalizes type 2-dominant inflammation in atopic dermatitis. **J Allergy Clin Immunol**. Submitted.
356. Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, Katoh N, Peris K, Puig L, Barbarot S, Mark T, Abildgaard Steffensen L, Tindberg AM, Wollenberg A. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. **Am J Clin Dermatol**. Submitted.
357. Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepletowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. Deucravacitinib efficacy in scalp psoriasis: a subset analysis of two phase 3 randomized trials (POETYK-1 PSO-1 and PSO-2). In preparation.
358. Blauvelt A, Papp KA, Gottlieb A, Armstrong A, Warren RB, Gallo G, See K, Burge R, Somani N, Paul C. A comprehensive review of ixekizumab in psoriasis. In preparation.
359. Gottlieb A, Gooderham M, Jarell A, Smith S, Green L, Gallo G, Konicek B, Burge R, Park SY, Blauvelt A. Absolute improvements in BSA and PASI at week 12 correlate with improvements in nail psoriasis, itch, and quality of life at week 24 in treatment of moderate-to-severe psoriasis: ixekizumab versus guselkumab. In preparation.
360. Eichenfield LF, Simpson EL, Papp K, Szepletowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS. Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two phase 3 studies. In preparation.
361. Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaci D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa RM, Banerjee S, Blauvelt A. Deucravacitinib in phase 3 plaque psoriasis trials: onset of action and maintenance of response. In preparation.
362. Thyssen JP, Silverberg JI, Ruano Ruiz J, Blauvelt A, Gubelin W, Simpson EL, Weidinger S, Valdez H, Terry KK, Biswas P, Güler E, Feeney C. Optimizing maintenance therapy in responders to abrocitinib induction: a post-hoc analysis of JADE REGIMEN. In preparation.

363. Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR, Wollenberg A. Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 and/or used rescue medication. In preparation.
364. Silverberg JI, Armstrong A, Blauvelt A, Simpson E, Reich K. Assessment of long-term efficacy and safety outcomes in clinical trials of systemic agents used for the treatment of moderate-to-severe atopic dermatitis. In preparation.
365. Blauvelt A, Silverberg JI, Calimlim BM, Liu Y, Platt A, Thyssen JP. Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2, and Heads Up studies. In preparation.
366. Lebwohl M, Warren RB, Menter A, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Sekaran C, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib 2-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials in plaque psoriasis. In preparation.
367. Blauvelt A, Alonso-Llamazares J, Bhatia N, Draelos ZD, DuBois J, Forman SB, Gooderham M, Green L, Guenther ST, Hebert AA, Lain E, Moore AY, Papp KA, Stein Gold L, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH. Roflumilast foam for seborrheic dermatitis: A phase 3 trial. In preparation.
368. Simpson EL, Kircik L, Blauvelt A, Kallender H, Wei S, Sturm D, Eichenfield LF. Efficacy, safety, and disease control with ruxolitinib cream in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of monotherapy. In preparation.
369. Blauvelt A, McLean RR, Beaty S, Sima AP, Low R, Jones EA, Stark JL, Lesser E, McClung L, Spitzer RL, Bagel J. Disease burden of patients with psoriasis who switch biologic therapy in real-world settings. In preparation.
370. Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis. In preparation.
371. Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espillat R, Sinval R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. In preparation.
372. Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield L, Eyerich K, Gooderham M, Guttman E, Hijnen DJ, Irvine A, Katoh N, Murrell D, Lesham YA, Levin A, Vittrup Nielsen I, Olydam JI, Orfali RL, Paller A, Renert-Yuval Y, Rosmarin D, Silverberg J, Thyssen J, Ständer S, Stefanovic N, Todd G, Yu J, Simpson E. A practical guide to using oral JAK inhibitors for atopic dermatitis from an Expert Committee of the International Eczema Council. In preparation.
373. Rudnicka L, Holmes S, Blauvelt A, Zlotogorski A, Ocampo Candiani J, Edwards RA, Bonfanti G, Sadrarhami MM, Wolk R, Tran H. Early eyebrow/eyelash regrowth predicts subsequent scalp hair regrowth in patients with alopecia areata treated

with ritlecitinib: *post hoc* analysis of the ALLEGRO phase 2b/3 study. In preparation.